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ABSTRACT 
The objective of this study is to determine if the effects of a high molecular 
weight sodium hyaluronate (HA) alone or in combination with triamcinolone acetate 
(TA) can mitigate chondrocyte proteoglycan catabolism caused by interleukin-1 (IL-1) 
administration.  Chondrocytes were collected from fetlock joints of ten horses euthanized 
for reasons unrelated to joint disease.  Chondrocyte pellets were treated with media 
(negative control); media containing IL-1 only (positive control); or media containing IL-
1 with HA only (0.5 or 2.0 mg/mL), TA only (0.06 or 0.6 mg/mL), or HA (0.5 or 2.0 
mg/mL) and TA (0.06 or 0.6 mg/mL) in combination.  Chondrocyte pellets were assayed 
for newly synthesized GAG, total GAG content, total DNA content, and mRNA levels of 
collagen type II, aggrecan, and COX-2.  The high concentration of HA (2.0 mg/mL) 
increased GAG synthesis while the high concentration of TA (0.6 mg/mL) decreased loss 
of GAG into the media.  Both the high concentration of HA and TA increased the total 
GAG content within the pellet.  There was no change in pellet DNA content with either 
treatment.  TA reduced COX-2 mRNA levels as well as aggrecan and collagen type II 
expression.  Treatment with HA had no effect on mRNA levels of COX-2, aggrecan or 
collagen type II.  These results indicate that the high concentration of HA or TA alone or 
in combination will mitigate effects of IL-1 administration on proteoglycan catabolism of 
equine articular chondrocytes. 
 iii 
 
 
 
 
 
To my parents 
 For always believing in me and encouraging me to reach for the stars 
 
 iv 
ACKNOWLEDGEMENTS 
I would like to acknowledge the support of the USDA Animal Health and Disease 
fund for providing financial backing for this project.  I would like to acknowledge all the 
people who made this project possible, especially my advisor, Dr. Allison Stewart, who 
painstakingly kept after me to finish this thesis.  Thank you so much for all your guidance 
and mentoring.  I could not have asked for a better teacher.  I would like to thank my 
committee members, Dr. Matthew Stewart, Dr. Christopher Byron, and Dr. Joan 
Jorgensen, for their support and constructive criticism in completing this project.  I would 
also like to thank the lab support staff, Holly Pondenis and Trina Kuykendall, and fellow 
graduate students, Dr. Sushmitha Durgam and Dr. Evelyn Caporali, who kept me 
company and answered my unending barrage of questions.  Additionally, I would like to 
thank my resident mates, Dr. Jennifer Barrett and Dr. Michael Karlin, who put up with 
me confiscating all the fetlock cartilage and then running in and out of the lab while 
trying to also work-up clinic cases.  Finally, a shout-out to my interns, Dr. Jessica Pallen, 
Dr. Stephanie Hill, Dr. Lara Quran, Dr. Sushmitha Durgam, Dr. Jill Eyles, Dr. Eric 
Carlson, and the fourth year students and veterinary technicians who made these last 
three years unforgettable.  
 
 
 v 
TABLE OF CONTENTS 
 
LIST OF TABLES         vi 
LIST OF FIGURES         vii 
CHAPTER 1. INTRODUCTION       1 
CHAPTER 2. LITERATURE REVIEW      5 
CHAPTER 3. MATERIALS AND METHODS     29 
CHAPTER 4. RESULTS        34 
CHAPTER 5. DISCUSSION        47 
REFERENCES         53  
APPENDIX A. ALCIAN BLUE PELLET DATA     70 
APPENDIX B. ALCIAN BLUE MEDIA DATA     78 
APPENDIX C. DMMB PELLET DATA      86 
APPENDIX D. DMMB MEDIA DATA      97 
APPENDIX E. DNA DATA        108 
 vi 
LIST OF TABLES 
 
Table 1.  Treatment Groups        33 
 vii 
LIST OF FIGURES 
 
Figure 1. Pellet GAG Synthesis       38 
Figure 2. Total GAG Synthesis       39 
Figure 3. Percent GAG Retained in the Pellet     40 
Figure 4. Percent GAG Released into the Media     41 
Figure 5. Total GAG Pellet Content       42 
Figure 6. Collagen Type II mRNA Levels      43 
Figure 7. Aggrecan mRNA Levels       44 
Figure 8. COX-2 mRNA Levels       45 
Figure 9. Histologic Examination       46 
 1 
CHAPTER 1. INTRODUCTION 
The horse industry generates an average of $39 billion annually in the United 
States and has a total impact of $101.5 billion on the United States Gross Domestic 
Product (Deloitte Consulting LLP, 2005).  There are approximately 9.2 million horses in 
the United States with 81% involved in recreation, showing, or racing (Deloitte 
Consulting, 2005).  The major cause of wastage in equine athletes is due to lameness 
associated with joint pain and osteoarthritis (Pool and Meager, 1990; Rossdale, et al., 
1985; Jeffcott, et al. 1982; and Stover, 2003).  Current therapies utilized in the treatment 
of lameness associated with osteoarthritis include oral supplements such as glucosamine 
and chondroitin sulfate, oral medications such as non-steroidal anti-inflammatories, and 
intra-articular medications such as corticosteroids, hyaluronic acid, polysulfated 
glycosaminoglycans, and interleukin-1 receptor antagonist protein (IRAP) (Goodrich, et 
al., 2006; Frisbie, et al., 2002).  While current clinical evidence suggests combination 
therapy with intra-articular corticosteroids and hyaluronic acid may be most beneficial, 
little scientific evidence has been published in this area.  The purpose of this study was to 
evaluate two commonly used intra-articular therapies, corticosteroids and hyaluronic acid 
(HA), in combination for treatment of osteoarthritis. 
Intra-articular injections of corticosteroids rapidly resolve joint inflammation, 
synovitis, and pain (Frisbie, et al., 1998; Shoemaker, et al., 1992; Murphy, et al., 2000; 
and Frisbie, et al., 1997).  Corticosteroids remain the gold standard for keeping horses 
with osteoarthritis in work while alleviating their pain (Frisbie, et al., 1997).  The anti-
inflammatory mechanisms of corticosteroids are two-fold.  Corticosteroids suppress 
arachidonic acid metabolism through lipocortin-induced phospholipase inhibition 
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(Gilron, 2004).  This inhibition helps to stabilize the phospholipids within the cell 
membrane, making them unavailable for entrance into the arachidonic cascade.  
Corticosteroids also block production of pro-inflammatory cytokines, such as interleukin-
1 (IL-1), by binding to cytoplasmic receptors and modulating gene transcription (Gilron, 
2004).  Two of the more common corticosteroids frequently used are methylprednisolone 
acetate (MPA) and triamcinolone acetate (TA).  Previous studies have shown higher 
doses of MPA can have detrimental effects both on normal and abnormal articular 
cartilage by impairing chondrocyte activity, inhibiting glycosaminoglycan (GAG) and 
proteoglycan synthesis within the articular cartilage matrix, and decreasing mRNA 
expression of collagen type II (Doyle, et al., 2005; Yates, et al., 2006; Frisbie, et al., 
1998; Shoemaker, et al., 1992; and Murphy, et al., 2000).  In contrast, studies on TA have 
shown many beneficial effects on abnormal articular cartilage.  In these studies, TA 
decreased IL-1 induced GAG degradation, increased proteoglycan synthesis, and 
protected chondrocyte viability (Frisbie, et al., 1997; Sandler, et al., 2004; and Dechant, 
et al., 2003).  Based on many studies, 6 to 18 mg of intra-articular TA is recommended 
for treatment in high motion joints (Carson, 2005).   
Clinically, HA has been used as a therapeutic treatment for osteoarthritis.  In a 
normal joint, HA is secreted into the synovial fluid by joint capsule synoviocytes and 
serves as boundary lubrication (Schmidt, et al., 2007).  It is also an important component 
of the articular cartilage where it binds to chondrocyte CD44 receptors and serves as a 
backbone of attachment sites for proteoglycan structures (Akmal, et al., 2005; Goodrich 
and Nixon, 2006).  Proteoglycans maintain the hydrostatic pressure of cartilage allowing 
resistance to compressive forces during weight bearing and is depleted first in the early 
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stages of osteoarthritis (Rydell, et al., 1970; Young, et al., 2006).  Previously documented 
beneficial effects of HA are increasing chondrocyte metabolism, increasing the GAG 
content within the cartilage matrix, and decreasing the activity of pro-inflammatory 
mediators resulting in decreased matrix degradation (Yates, et al., 2006; Akmal, et al., 
2005; Rydell, et al., 1970; Iwata, 1993; and Moreland, 2003).  However, it remains 
uncertain if the molecular weight of various HA products plays a significant factor in the 
effectiveness of these functions.  Several studies have demonstrated that a high molecular 
weight HA may have a longer efficacy and increased metabolic and anti-inflammatory 
properties when compared to a low molecular weight HA (White, et al., 1999; 
McIlwraith, 1996; Phillips, 1980; and Cheney, 1996).  However, other studies claim little 
to no difference between high and low molecular weight HA products (Aviad and Houpt, 
1994; Aviad, et al., 1988).   
Two recently published studies have evaluated combination therapy with MPA 
and HA both on normal equine cartilage explants and an IL-1-induced inflammatory 
model of chondrocyte metabolism (Doyle, et al., 2005; Yates, et al., 2006).  The cartilage 
explant study demonstrated detrimental effects of MPA on normal articular cartilage and 
showed addition of a medium-molecular weight HA had little effect on the corticosteroid-
induced proteoglycan catabolism of the cartilage matrix (Doyle, et al., 2005).  The later 
study showed beneficial effects on proteoglycan metabolism by using lower doses of 
MPA and a medium-molecular weight HA on inflamed (IL-1 treated) chondrocyte pellets 
(Yates, et al., 2006).  The purpose of this study was to evaluate the effects of two of the 
most commonly used intra-articular therapies in high motion joints.  This included a 
medium-acting corticosteroid (TA) and a high molecular weight HA.  Our hypothesis 
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was that administration of HA alone or in combination with TA would mitigate the 
chondrocyte proteoglycan catabolism caused by IL-1 administration. 
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CHAPTER 2. LITERATURE REVIEW 
2.1 Structure and Function of Healthy Synovial Joints 
 Synovial, or diarthrodial, joints serve two distinct functions in the body.  First, 
they allow movement.  Second, they allow the transfer of load between bones.  Synovial 
joints consist of a joint capsule lined with synovium, synovial fluid, articular cartilage 
and its associated extracellular matrix.  Each of these components plays a crucial role in 
joint homeostasis to allow proper functioning of the joint through movement and load 
transfer. 
 
2.1.1 Synovium 
  The inner surface of the joint capsule is lined with a synovial membrane.  This 
synovium consists of vascularized connective tissue that lacks a basement membrane 
(Todhunter, 1996b; Henderson, et al., 1985).  The blood supply to the synovium branches 
from the joint capsule and extend into the subsynovium, within 5 to 10µm of the intimal 
surface (Todhunter, 1996b).  These vessels are also accompanied by lymphatics and 
nerves.  The predominant cell type in the synovium consists of synoviocytes.  There are 
several different types of synoviocytes: type A, type B, and type C (Saw, 2007; Frisbie, 
2006; Todhunter, 1996b; Iwanaga, et al., 2000; Gerwin, et al., 2006; Burmester, et al., 
1983; Sutton, et al., 2009).  Type A synoviocytes are important in phagocytosis 
(Burmester, et al., 1983; Sutton, et al., 2009).  Type B synoviocytes are important in 
secretory functions and are the main producers of synovial fluid for the joint (Iwanaga, et 
al., 2000).  In particular, these cells produce and secrete hyaluronan which serves as a key 
component in boundary lubrication and load transfer (Todhunter, 1996b; Sutton, et al., 
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2009).  Lubricin, another key component of boundary lubrication, is also synthesized by 
the synovium (Todhunter, 1996b; Saw, et al., 2007; Schmidt, et al., 2007a).  Less 
information is known about the third type of synoviocytes, type C, which consist of 
intermediate or undifferentiated cells that may serve a reparative role in synovium (Saw, 
2007; Frisbie, 2006; Todhunter, 1996b; Gerwin, et al., 2006; Sutton, et al., 2009).   
 
2.1.2 Synovial Fluid 
 Synovial fluid, produced by the synovium, is an ultrafiltrate of blood plasma that 
also contains a high concentration of hyaluronan (Gerwin, et al., 2006; Todhunter, 1996b; 
Frisbie, 2006; Walsh, et al., 1997; Goodrich, et al. 2006).  In addition, other molecules 
such as proteinase, collagenases, and prostaglandins, and cell types such as monocytes, 
lymphocytes and other polymorphonuclear leukocytes, are present (Todhunter, 1996b).  
However, normal equine synovial fluid contains less than 500 nucleated cells/µL 
(Todhunter, 1996b).  Due to the absence of an intimal basement membrane and the close 
proximity of capillaries to the synovium, fluid exchange between plasma and synovial 
fluid can occur.  This facilitates the exchange of solutes governed by Starling’s forces 
(hydrostatic and oncotic pressure differences between the plasma and synovial fluid) 
(Levick, 1984).   
 The synovial fluid provides nutrients to the avascular articular cartilage and also 
serves as joint lubrication (Saw, et al., 2007; Gerwin, et al., 2006; Frisbie, 2006; Aigner, 
et al., 2006; Sutton, et al., 2009).  The increased viscosity of the synovial fluid is 
attributed to the high concentration of hyaluronan (Gerwin, et al., 2006; Todhunter, 
1996b; Hadler, et al., 1977).  Normal equine synovial fluid contains roughly 0.5 mg/mL 
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hyaluronan (Saari, et al., 1989).  The viscous nature of the synovial fluid allows it to 
provide joint lubrication to the synovial membrane and the articular cartilage through two 
different mechanisms: fluid film lubrication and boundary lubrication (Saw, et al., 2007; 
Davis, et al., 1978; Ateshian, et al., 2005; Schmidt, et al., 2007b; Frisbie, 2006).  Fluid 
film lubrication involves pressurized fluid separating the joint surfaces.  This occurs 
when a load is applied and interstitial fluid becomes pressurized causing leakage out of 
the extracellular matrix to form a fluid film between the opposing joint surfaces.  The 
viscosity of this fluid increases to an osmotic pressure equivalent to the pressure being 
applied by the load (Todhunter, 1996b; Saw, et al., 2007; Davis, et al., 1978).  Boundary 
lubrication involves a layer of lubrication along both articular surfaces that prevents 
direct surface to surface contact (Saw, et al., 2007; Schmidt, et al., 2009b).  Lubricin, a 
glycoprotein, is the key lubricating component in synovial fluid and works in conjunction 
with hyaluronic acid to decrease resistance to motion along the articular cartilage 
(Gerwin, et al., 2006; Saw, et al., 2007; Swann, et al., 1985).  Hyaluronic acid is the 
major component responsible for lubrication of the synovial membrane surface (Davis, et 
al., 1978).  Boundary lubrication is critical to the protection and maintenance of joint 
surfaces to mitigate normal wear (Schmidt, et al., 2007b). 
 
2.1.3 Articular Cartilage 
 Articular cartilage is the weight-bearing component of the synovial joint.  It is 
avascular, aneural, and alymphatic (Dijkgraaf, et al., 1995; Saw, et al, 2007, Frisbie, 
2006; Aigner, et al., 2006).  Nutrition and elimination of waste products are dependent on 
diffusion through the extracellular matrix and the synovial membrane (Frisbie, 2006; 
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Dijkgraaf, et al., 1995; Gerwin, et al., 2006).  Pain perception and proprioception are 
dependent on the nerve endings in the synovial membrane, joint capsule and underlying 
subchondral bone (Dijkgraaf, et al., 1995; Todhunter, 1996b).  Articular cartilage is a 
connective tissue composed of chondrocytes and a specialized extracellular matrix 
(Frisbie, 2006; Gerwin, et al., 2006; Dijkgraaf, et al., 1995; Saw, et al., 2007).   
Articular cartilage is arranged into the superficial zone, the transitional zone, the 
radial zone, the tidemark, and the calcified zone (Todhunter, 1996b; Saw, et al., 2007; 
Frisbie, 2006; Aigner, et al., 2006).  The superficial zone (or tangential zone) has the 
highest cell density, with small and flat chondrocytes oriented parallel to the articular 
surface (Todhunter, 1996b).  In the superficial zone, collagen fibrils are tangential to the 
surface (Frisbie, 2006).  The transitional zone contains large and more rounded 
chondrocytes when compared to the superficial zone (Todhunter, 1996b; Frisbie, 2006).  
In the transitional zone, collagen fibrils are arranged in a complex 3-dimensional fashion 
with longer fibrils oriented somewhat perpendicular to the surface and shorter fibrils 
branching off the longer ones (Todhunter, 1996b; Clark, 1985).  The radial zone 
chondrocytes are larger and oriented perpendicular to the articular surface (Saw, et al., 
2007; Frisbie, 2006).  In the radial zone, collagen fibrils are larger and positioned 
predominantly perpendicular to the articular surface (Todhunter, 1996b).  The collagen 
meshwork is more rigid in the radial zone than in the transitional zone.  The tidemark is 
the junction between the noncalcified cartilage and calcified cartilage observed on 
histological sections (Frisbie, 2006).  The calcified zone contains the cement line formed 
during the endochondral ossification of the growth plate.  The collagen fibrils are 
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arranged perpendicular to the articular surface and create a rigid meshwork interspersed 
with hydroxyapatite crystals (Todhunter, 2006b).  
 
2.1.3.1 Chondrocytes 
 The major cellular component of articular cartilage is the chondrocyte.  
Chondrocytes compose anywhere from 1 to 12% of the articular cartilage makeup 
(Todhunter, 1996b).  Nutrition is provided from the synovial fluid as load compression 
forces affect movement of interstitial fluid in and out of the extracellular matrix carrying 
nutrition towards the chondrocytes and transporting waste products away towards the 
synovial fluid (Gerwin, et al., 2006; Frisbie, 2006; Dijkgraaf, et al., 1995).  While they 
constitute only a very small fraction of the articular cartilage volume, they are responsible 
for production and maintenance of the entire extracellular matrix, including collagen, 
proteoglycans and numerous enzymes for cartilage metabolism (Todhunter, 1996b; Saw, 
et al., 2007).  In addition, chondrocytes also have control over the location of adjacent 
extracellular components through specific cell membrane receptors (Dijkgraaf, et al., 
1995; Frisbie, 2006).  These cell receptors are integral membrane proteins that contain 
extracellular glycosaminoglycan chains capable of binding collagen and fibronectin in the 
extracellular matrix (Dijkgraaf, et al., 1995).   
 
2.1.3.2 Extracellular Matrix 
 The extracellular matrix of articular hyaline cartilage consists of water, collagen, 
proteoglycans, structural glycoproteins, and small amounts of lipids and inorganic 
components (Dijkgraaf, et al., 1995).  The high water content (70 to 80%) of the hyaline 
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cartilage extracellular matrix is responsible for the translucent, glassy appearance 
(Todhunter, 1996b).  The majority of the dry weight of articular cartilage is due to the 
collagen (50-60%) and proteoglycan (20-40%) volume, with the remainder of the dry 
weight constituting glycoproteins (10%), minerals (3%), and lipids (1%) (Todhunter, 
1996b).   
 The majority of the collagen in articular cartilage is type II (85-95% of the total) 
(Saw, et al., 2007; Mayne, et al., 1986; Eyre, et al., 1991; Vachon, et al., 1990).  The 
collagen fibrils are arranged in bundles, creating a meshwork kept together by cross-links 
with collagen type IX and anchoring proteins such as fibronectin (Howell, et al., 1992; 
Dean, 1991).  This network provides the tensile strength and shape of articular cartilage 
and counteracts the swelling pressure of the hydrophilic proteoglycans within the 
extracellular matrix (Maroudas, 1979; Roughly, et al., 1994; Frisbie, 2006).   
 Proteoglycans are the other major solid component of the extracellular matrix.  
They can be divided into two broad categories including large aggregating proteoglycans 
(aggrecan) and small nonaggregating proteoglycans (decorin, biglycan, and 
fibromodulin) (Platt, 1996; Frisbie, 2006).  These structures are complex macromolecules 
that consist of a core protein covalently linked to glycosaminoglycan chains of varying 
lengths and bound to hyaluronan via a link protein (Hamerman, et al., 1985; Dijkgraaf, et 
al., 1995; Frisbie, 2006).  The major glycosaminoglycans within the extracellular matrix 
are chondroitin 4-sulfate, chondroitin 6-sulfate, keratan sulfate, and hyaluronan.  These 
glycosaminoglycans constitute about 90% of the glycosaminoglycan side chains 
(Hamerman, et al., 1985; Howell, 1989; Platt, 1996; Dijkgraaf, et al., 1995).  Other 
smaller glycosaminoglycan side chains found within the extracellular matrix include 
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dermatan sulfates (biglycan and decorin) and fibromodulin (Todhunter, 1996b; Platt, 
1996; Hedlund, et al., 1994; Wiberg, et al., 2001).  These proteoglycan structures are 
intertwined within the collagen network, and due to their high water-binding capacity, 
also aid in providing the cartilage with its resilience, elasticity, sheer strength and self-
lubrication (Aigner, et al., 2006; Dijkgraaf, et al., 1995).   
 Hyaluronan has a unique glycosaminoglycan structure.  It is not attached to a core 
protein during synthesis and it is the only glycosaminoglycan that is not sulfated 
(Todhunter, 1996b).  In articular cartilage, the molecular weight of hyaluronan varies 
from 3 x 102 to 1 x 106 kDa (Laurent, et al., 1986; Todhunter, 1996b).  A large portion of 
the hyaluronan found in articular cartilage is associated with aggrecan, forming larger 
proteoglycan structures (Todhunter, 1996b; Roughley, et al., 1994).  In addition to 
binding aggrecan, hyaluronan also binds to CD44 receptors on chondrocyte cell 
membranes and to other molecules in the extracellular matrix (Todhunter, 1996b; Ishida, 
et al., 1997). 
 Aggrecan is a core protein that contains chondroitin sulfate and keratan sulfate 
glycosaminoglycan side chains (Hascall, et al., 1974; Todhunter, 1996b).  It is most often 
found bound in large aggregates to hyaluronan (Hascall, et al., 1974; Todhunter, 1996b; 
Lohmander, 1988; Frisbie, 2006).  As many as 100 aggrecan monomers can be bound to 
a single hyaluronan chain by link proteins (Lohmander, 1988; Akeson, 2003).  These link 
proteins simultaneously bind aggrecan and hyaluronan to make the dissociation of the 
two monomers difficult under physiologic conditions (Akeson, 2003; Franzen, et al., 
1981; Hardingham, et al., 1979; Perin, et al., 1987). 
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 The small nonaggregating proteoglycans can be subdivided into two groups: 
chondroitin sulfate-dermatan sulfate proteoglycans and keratan sulfate proteoglycans 
(Todhunter, 1996b).  Heparan sulfate proteoglycans have been identified on the 
chondrocyte cell surface, but have yet to be identified in the extracellular matrix 
(Todhunter, 1996b).  Three small nonaggregating proteoglycans have been identified 
within the extracellular matrix of the articular cartilage: biglycan, decorin, and 
fibromodulin (Platt, 1996; Rosenberg, 1992; Hedlund, et al., 1994; Wiberg, et al., 2001).  
Little is understood about the in vivo function of these small proteoglycans, but in vitro 
studies suggest that they may play a role in collagen fibril size, and the multiplication, 
differentiation, and migration of cells (Todhunter, 1996b; Hedbom, et al., 1989; 
Rosenberg 1992). 
The structural glycoproteins are noncollagenous and nonproteoglycan structures 
whose functions are relatively unknown, except for the link proteins (Fife, et al., 1993; 
Todhunter, 1996b).  In general, the structural glycoproteins interact with cellular 
receptors and regulate adhesion, migration, proliferation, and differentiation of the 
chondrocytes (Trelstad, 1989; Dean, et al., 2003).  The two main structural glycoproteins 
are fibronectin and laminin.  Fibronectin is a large, adhesive glycoprotein that aggregates 
near the chondrocyte cell membrane and in the extracellular matrix (Dijkgraaf, et al., 
1995).  Laminin is found predominantly in the basement membranes and as a receptor-
bound component of the cell surface (Dijkgraaf, et al., 1995).  Chondronectin has also 
been found to have adhesive properties, binding chondrocytes to type II collagen fibrils 
(Hewitt, et al., 1982). 
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2.1.3.3 Chondrocyte Metabolism and Extracellular Matrix Turnover 
 Chondrocytes account for a small volume of the articular cartilage.  However, 
they are responsible for the synthesis and degradation of all extracellular matrix 
components (Dijkgraaf, et al., 1995; Todhunter, 1996b).  Collagen begins translation in 
the rough endoplasmic reticulum of the chondrocyte where it starts as a procollagen 
molecule that subsequently undergoes posttranslational hydroxylation and glycosylation.  
The hydroxylase enzymes that act as a catalyst for the hydroxylation are kept in an active 
form by ascorbic acid (Pacifici, et al., 1988; Todhunter, 1996b).  The collagen molecules 
are then woven into a triple helix structure in the Golgi apparatus and secreted into the 
extracellular matrix.  The N- and C-terminal propeptides are then cleaved and the fibrils 
are crosslinked (Leblond, 1989; Todhunter, 1996b). 
 Proteoglycans are also synthesized by the chondrocytes.  The core protein is the 
first part to be synthesized within the rough endoplasmic reticulum.  It then undergoes 
addition of glycosaminoglycan chains in the Golgi apparatus, followed by sulfation of 
these chains (Lohmander, et al., 1986; Platt, 1996).  Because sulfation is a late stage in 
the synthesis of the proteoglycan molecules, it is a convenient method of monitoring 
proteoglycan synthesis by radioactive labeling with 35SO4 (Todhunter, 1996b).  
Hyaluronan lacks a protein core and is therefore synthesized by a different route.  Its 
synthesis occurs on the inner plasma membrane before extruding into the extracellular 
space (Prehm, 1983; Prehm, 1984).  Because it does not undergo synthesis in the Golgi 
apparatus, hylauronan is not sulfated (Todhunter, 1996b).    
Chondrocytes are also responsible for maintenance, organization and regulation of 
the extracellular matrix.  They receive chemical and hormonal stimuli from the synovial 
 14 
fluid that diffuses into the extracellular matrix to interact with the chondrocytes 
(Todhunter, 1996b).  In response, they secrete and regulate proteases, cytokines, and 
growth factors to maintain this homeostasis (Dijkgraaf, et al., 1995; Platt, 1996; Frisbie 
2006).  The molecules that may diffuse into the cartilage from the synovial fluid are 
regulated by the proteoglycan concentration within the extracellular matrix; larger 
molecules being unable to diffuse through high concentrations of proteoglycan 
(Maroudas, 1970; Maroudas, 1976; Maroudas, et al., 1986).  Cytokines and growth 
factors are polypeptides that influence the growth, differentiation and metabolic activity 
of the chondrocytes (Howell, et al., 1992; Dijkgraaf, et al., 1995).  In general, cytokines 
act in a catabolic fashion and growth factors act in an anabolic fashion in the articular 
cartilage.  Cytokines, such as interleukins and tumor necrosis factor α, can be synthesized 
by chondrocytes, synovium or inflammatory cells and act to stimulate proteoglycan 
depletion (Dijkgraaf, et al., 1995; Todhunter, 1996b).  They act primarily at the cell 
surface receptors and the signal is then relayed to the nucleus and results in transcription 
of factors resulting in decreased proteoglycan synthesis and up-regulation of proteases 
which result in increased proteoglycan degradation (Pelletier, et al., 1993; Howell, et al., 
1992).  Cytokine effects can also be negated by receptor antagonists such as interleukin-1 
receptor antagonist (IL-1ra) and binding proteins such as tumor necrosis factor-binding 
protein (TNF-BP) (Pelletier, et al., 1991).   
Growth factors can antagonize the catabolic effects of cytokines and stimulate 
proteoglycan synthesis (Tyler, et al., 1992; Dijkgraaf, et al., 1995).  Several growth 
factors, such as insulin-like growth factor (IGF) and transforming growth factor (TGF), 
have been identified as having beneficial effects on proteoglycan synthesis in articular 
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cartilage (Tesch, et al., 1992; Roberts, et al., 1990).  Both of these growth factors have 
been shown in vitro to increase the synthesis of proteoglycan and several extracellular 
matrix components (Morales, 1991; Morales, et al., 1988; Morales, 1993; Platt, et al., 
1995; Platt, 1996).  In addition, IGF and TGF act to negate the detrimental effects of 
certain cytokines by decreasing synthesis of certain proteinases and increasing synthesis 
of their corresponding inhibitors (Pelletier, et al., 1991; Dijkgraaf, et al., 1995; Morales, 
et al., 1988). 
Interleukin-1 (IL-1) activity has been reported in normal equine synovial fluid and 
plays a major role in the homeostasis of the normal cartilage matrix (May, et al., 1992; 
Tyler, et al., 1992).  In vitro studies have demonstrated its effects on upregulation of 
degradative enzymes (proteases) and other inflammatory cytokines (IL-6, IL-8, and TNF) 
(Tyler, et al., 1992; Dijkgraaf, et al., 1995; Platt, et al., 1994; Arner, et al., 1989; Gouze, 
et al., 2001).  In addition, several studies have shown addition of IL-1 stimulating an 
upregulation of protease inhibitors such as tissue inhibitor of metalloprotease (TIMP) and 
plasminogen activator inhibitor (PAI) suggesting that IL-1 plays a more complex role in 
cartilage homeostasis and regulation of enzymatic activity (Sato, et al., 1990; Treadwell, 
et al., 1991).   
IL-1 is a potent stimulator of metalloproteinase secretion by normal chondrocytes 
(Tetlow, et al., 2001; Dijkgraaf, et al., 1995; Bau, et al., 2002).  Two of the more studied 
matrix metalloproteinases (MMP) that have been shown to have a significant effect on 
articular cartilage have been MMP-1 (collagenase) and MMP-3 (stromelysin) (Martel-
Pelletier, 2004).  Collagenase acts to break down the triple helix structure of the collagen 
fibrils, leaving the fragments susceptible to further proteolysis (Dijkgraaf, et al., 1995; 
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Gross, et al., 1980; Murphy, et al., 1993; Cawston, et al., 1999).  Stromelysin has 
degradative effects on collagen as well as the proteoglycan components of the 
extracellular matrix including aggrecan and link proteins (Martel-Pelletier, et al., 1994; 
Bonassar, et al., 2005; Lark, et al., 1997; Nguyen, et al., 1989; Flannery, et al., 1992; Wu, 
et al., 1991).  In normal articular cartilage, these MMPs are held in check by protease 
inhibitors like TIMP and PAI, which have been shown to be present at slightly higher 
concentrations than MMPs (Hamilton, et al., 1991; Dean, et al., 1989; Woessner, et al., 
1991; Little, et al., 1999).  Recently, another group of metalloproteinases have been 
identified that play a crucial role in aggrecan breakdown within the extracellular matrix 
(Tang, et al., 2001; Cal, et al., 2002).  These are the aggrecanases, otherwise known as “A 
Disintegrin and Metalloproteinase with ThromboSpondin motif” (ADAMTS) (Huang, et 
al., 2008; Nagase, et al., 2003).  It has been suggested that both ADAMTS-4 and 
ADAMTS-5 are constitutively expressed within normal synoviocytes and chondrocytes 
(Yamanishi, et al., 2002; Vankemmelbeke, et al., 2001).  These ADAMTS are kept in 
check by TIMPs during normal cartilage homeostasis (Kashiwagi, et al., 2001; 
Hashimoto, et al., 2001). 
 
2.2 The Pathophysiology of Osteoarthritis 
 Degeneration of the articular cartilage has been considered the “sine qua non of 
osteoarthritis” (McIlwraith, 1982).  Three main concepts have been proposed as potential 
etiologies for osteoarthritis (Dijkgraaf, et al., 1995).  The first concept is based on 
mechanical loading and biomaterial failure of the extracellular matrix and/or chondrocyte 
injury (Dijkgraaf, et al., 1995; Howell, 1989; Howell, et al., 1992; McIlwraith, 1996a).  
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This can occur through overloading (absolute or relative) or underloading of the cartilage.  
Absolute overloading occurs in normal articular cartilage when abnormal or repetitive 
mechanical loads exceed its adaptive capacity (Dijkgraaf, et al., 1995).  Relative 
overloading occurs in abnormal articular cartilage when normal mechanical loads exceed 
the intrinsically reduced capacity of that cartilage (Dijkgraaf, et al., 1995).  Underloading 
occurs when mechanical loads are below the normal physiologic range for that individual 
(Dijkgraaf, et al., 1995).  The second concept involves failure of intrinsic chondrocyte-
controlled remodeling and repair in response to insult (Dijkgraaf, et al., 1995; Howell, et 
al., 1992; McIlwraith, 1996a).  A primary injury will disrupt the homeostatic balance of 
the extracellular matrix by the chondrocytes, resulting in accelerated extracellular matrix 
degradation (Dijkgraaf, et al., 1995; Howell, 1989).  The third proposed concept involves 
extracartilagenous factors that may be the primary instigator, resulting in secondary 
cartilage changes (Dijkgraaf, et al., 1995; Howell, et al., 1992; McIlwraith, 1996a).  
These extracartilagenous factors may include subchondral bone microfractures, synovial 
responses such as changes in the synovial membrane or a reduction in the quality or 
quantity of synovial fluid, bony remodeling, and vascular changes (Dijkgraaf, et al., 
1995, McIlwraith, 1996).  Because osteoarthritis may have several different etiologies 
and manifest in several different ways, it has become necessary to classify the different 
types of osteoarthritis as type 1, type 2, and type 3 (McIlwraith, 1996a; Howell, et al., 
1992).  Type 1 is considered osteoarthritis “associated with synovitis and capsulitis” 
(McIlwraith, 1996a).  Type 2 is considered osteoarthritis secondary to other problems 
such as intra-articular fractures, osteochondrosis, subchondral bone disease, and septic 
arthritis (McIlwraith, 1996a; Howell, et al., 1992).  Type 3 is considered to be 
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osteoarthritis as “an incidental or nonprogressive articular cartilage erosion” (McIlwraith, 
1996a).   
 Osteoarthritis has commonly been considered a degenerative condition of the 
articular cartilage, but the synovium may also play a role in the development and 
progression of the disease state (McIlwraith, 1996; Fell, et al., 1977; Smith, et al., 1997; 
Fiorito, et al., 2005; Sutton, et al., 2009).  Trauma to the synovium occurs with repeated 
cyclic loading and results in the release of degradative enzymes, cytokines, and other 
inflammatory mediators (Evans, 1992; McIlwraith, 1982).  In addition, the presence of 
IL-1 stimulates synthesis of such products as fibronectin and type I and type III collagen 
by synoviocytes, possibly attributing to the development of joint capsule fibrosis 
(Dijkgraaf, et al 1995; Haraoui, et al., 1991; Sledge, 1989).  The presence of synovitis 
also causes an increase in intra-articular temperature which increases the rate of 
enzymatic activity, further accelerating the degradation process (Sledge, 1989).  Joint 
effusion resulting from inflammation may also affect the intra-articular pressure 
(Dijkgraaf, et al., 1995).  Normal pressure within most joints at rest is 1 to 2 mmHg 
subatmospheric (Stewart, 1999).  Flexion of the joint increases the intra-articular pressure 
by as much as 3 mmHg (Stewart, 1999).  However, in effusive joints, the resting intra-
articular pressure may be slightly over atmospheric pressure (Stewart, 1999).  With 
flexion during exercise, the atmospheric pressure may exceed 60 mmHg (Stewart, 1999).  
This increase in pressure may compromise the synovial blood flow and diffusion of 
nutrients through the articular cartilage to supply the chondrocytes, thereby impairing 
chondrocyte nutrition (Dijkgraaf, et al., 1995; McIlwraith, 1996a).  This compromise in 
blood flow could also potentially lead to reperfusion injury as the joint moves through a 
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range of motion (Stewart, 1999; Levick, 1990; McIlwraith, 1996a; Merry, et al., 1991).  
Flexion of the effused joint would impair synovial blood flow leading to production of 
xanthine oxidase (Stewart, 1999; McIlwraith, 1996a; Allen, et al., 1989; Blake, et al., 
1989).  Upon relaxation of the joint, reperfusion would occur as well as the production of 
oxygen-derived free radicals leading to further chondrocyte and extracellular matrix 
damage (Stewart, 1999; McIlwraith, 1996a; Allen, et al., 1989). 
 In the horse, trauma is considered the most important initiating event in the 
development of osteoarthritis (McIlwraith, 1982; McIlwraith, 1996a; Goodrich, et al., 
2006).  Many factors may predispose the joints to trauma, including joint instability, 
fracture, faulty conformation, improper shoeing/imbalance, and type of work being 
performed (McIlwraith, 1982; McIlwraith, 1996a; Goodrich, et al., 2006).  These factors 
lead to abnormal or repetitive biomechanical loading resulting in trauma to the articular 
cartilage and synovium (Goodrich, et al., 2006; McIlwraith, 1996a).   
 Progression of osteoarthritis can be divided into several stages, with each stage 
exhibiting increasing joint degradation (Howell, et al., 1989).  The initial stage occurs 
after a primary insult and involves cartilage degradation with attempts at repair (Howell, 
et al., 1989; Dijkgraaf, et al., 1995).  Histologically, this stage exhibits proliferation of 
chondrocytes as they increase their metabolic activity in an attempt to repair the damage 
inflicted upon the articular cartilage (Dijkgraaf, et al., 1995; de Bont, et al., 1985).  Most 
importantly, there is a loss of proteoglycan from the extracellular matrix at this initial 
stage (McIlwraith, 1996a; Dijkgraaf, et al., 1995; Nelson, et al., 2006).  Biochemically, 
there is an increase in synthesis of DNA and extracellular matrix components mediated 
by growth factors until a balance between synthesis and degradation has been reached 
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(Dijkgraaf, et al., 1995; Howell, et al., 1993).  The next stage is reached when the 
degradation of the extracellular matrix by proteases has exceeded the synthesis by 
chondrocytes (Dijkgraaf, et al., 1995; Howell, et al., 1989).  Histologically, this early 
stage is characterized by focal swelling of the articular cartilage, cartilage surface 
irregularities, disorganization of the collagen network, chondrocyte proliferation followed 
by necrosis, and uneven staining of proteoglycan in the extracellular matrix (Mankin, et 
al., 1989; de Bont, et al., 1985; de Bont, et al., 1985b).  Biochemically, there is still 
increased synthesis of DNA, proteoglycans, collagen and structural glycoproteins 
(Dijkgraaf, et al., 1995; McIlwraith, 1996a).  In addition, proteolytic enzyme synthesis 
and release is increased while protease inhibitor synthesis may be decreased (Dijkgraaf, 
et al., 1995; Yamada, et al., 1987).  However, while the production of proteoglycan is 
increased, the composition of these newly synthesized proteoglycans is abnormal 
(Dijkgraaf, et al., 1995; Vasan, 1980).  The glycosaminoglycan chains are shorter, the 
concentrations of various glycosaminoglycans are altered, and normal aggregation with 
hyaluronan is altered (Dijkgraaf, et al., 1995; Howell, 1989).  The disruption of the 
collagen network allows increased water retention by the proteoglycans of the 
extracellular matrix and accounts for the swelling of the articular cartilage seen 
microscopically (Maroudas, 1976b; Sweet, et al., 1977; McIlwraith, 1996a; Aigner, et al., 
2006; Goodrich, et al., 2006).   
As the disease process progresses, further degradation of the articular cartilage is 
observed (Dijkgraaf, et al., 1995).  Histologically, increasing numbers of chondrocytes 
will undergo degradation and necrosis and the articular surface will be further damaged 
showing fibrillation, detachment, and thinning (Dijkgraaf, et al., 1995; de Bont, et al., 
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1985b).  The collagen network shows further disorganization and loss of metachromasia 
in the extracellular matrix when staining for proteoglycan content (de Bont, et al., 1985; 
Hough, et al., 1989; Dijkgraaf, et al., 1995).  Biochemically, synthesis of extracellular 
matrix components has been inhibited and synthesis of proteases has increased due to 
constant stimulus by cytokines IL-1 and TNF-α (Dijkgraaf, et al., 1995).  It has been 
reported that osteoarthritic cartilage has increased cytokine receptors on the chondrocyte 
cell membrane making Il-1 and TNF-α more apt to stimulate production of proteases, 
especially metalloproteinases, and inhibit any attempt by the chondrocytes to repair the 
damage (Aigner, et al., 2006; Fernandes, et al., 2002; McIlwraith, 1996a; Lefevre, et al., 
1990).  Matrix metalloproteinases (MMPs) and aggrecanases (ADAMTS) are considered 
key players in the degradation of the extracellular matrix through their destruction of 
collagen and proteoglycan (Clegg, et al., 1997; Gerwin, et al., 2006; Tang, et al., 2001; 
Sandy, et al., 2001; Cal, et al., 2002; Martel-Pelletier, et al., 2000).  Tissue inhibitors of 
metalloproteinases (TIMPs) keep the MMPs and ADAMTS under tight control in normal 
cartilage, but in osteoarthritic conditions, a deficiency in TIMPs allow the MMPs and 
ADAMTS to further degrade the extracellular matrix (Woessner, et al., 1991; Yamada, et 
al., 1987; Dean, et al., 1984; Dean, et al., 1987).  In addition to stimulating synthesis and 
release of other cytokines and proteolytic enzymes, IL-1 also stimulates the 
chondrocytes, synovial cells and inflammatory cells to synthesize and release arachidonic 
acid metabolites such as prostaglandin E2 (PGE2) and leukotrienes (May, et al., 1981; 
Dayer, et al., 1986; Todhunter, et al., 1990: von Rechenberg, et al., 2000).  PGE2 in joints 
have been shown to have several effects ranging from enhancement of pain perception 
and vasodilation to proteoglycan depletion from the extracellular matrix and bone 
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demineralization (McIlwraith, 1996a; Attur, et al., 2008; Miyaura, et al., 2000; Stock, et 
al., 2001).   
 
2.3 Current Treatment of Osteoarthritis 
 Current therapy for osteoarthritis consists of both medical and surgical options 
designed to control inflammation as well as minimize further damage to the articular 
cartilage and mitigate degenerative changes associated with progressing stages of 
osteoarthritis.  Medical therapy consists of rest/physical therapy, oral joint supplements 
such as glucosamine and chondroitin sulfate, and oral or injectable medications such as 
nonsteroidal anti-inflammatories, corticosteroids, hyaluronic acid, and polysulfated 
glycosaminoglycans (Goodrich, et al. 2006).  The recent development of interleukin-1 
receptor antagonist protein (IRAP) is also another viable therapeutic option (Frisbie, et 
al., 2002).  Surgical options for treatment of osteoarthritis involve joint lavage, 
arthroscopy/arthrotomy, or arthrodesis (McIlwraith, et al., 1996b).  Recently, there have 
also been attempts at surgical joint resurfacing in an effort to repair cartilage defects that 
could eventually lead to chronic inflammation and osteoarthritis (McIlwraith, et al., 
1996c).  With all these therapeutic options available, the mainstay of treatment regimes 
for allowing horses to return promptly to athletic function remains intra-articular 
injections of corticosteroids and hyaluronic acid (Frisbie, et al., 1997). 
 
2.3.1 Corticosteroids 
 Corticosteroids are potent anti-inflammatory agents that are routinely injected into 
equine joints to minimize pain and inflammation associated with trauma-induced joint 
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disease (Trotter1996b).  Controversy still remains over relative risk/benefit ratios 
associated with intra-articular corticosteroid use.  However, recent studies have focused 
on the intra-articular effects of corticosteroids on both the biochemical and morphologic 
changes within the articular cartilage with and without exercise, and the metabolism of 
the extracellular matrix by the chondrocytes and hyaluronic acid production by the 
synovial membrane (Trotter 1991; Shoemaker 1992; Foland 1994; Frisbie 1997; Frisbie 
1998; Todhunter 1993; Roneus 1993; Tulamo RM, 1991).  Ultimately, judicious use, as 
well as type of corticosteroid used, concentration, duration of exposure, and other tissue 
and cell variables play a role in the corticosteroid effects on articular cartilage (Goodrich 
2006). 
 All corticosteroids consist of twenty-one carbon molecules that are arranged in 
three six-carbon rings and one five-carbon ring.  The biologically active form contains a 
β-hydroxyl group at C-11 of the molecule and thus does not require biotransformation in 
the liver (Trotter 1996b).  Solubility of synthetic corticosteroid preparations determines 
rate of absorption and duration of action.  Acetate and acetonide esters, such as 
methylprednisolone acetate and triamcinolone acetonide, are more lipid soluble and as a 
result have a delayed absorption rate and a longer duration of action (Trotter 1996b).  
Another important factor to consider in the duration and onset of action is the rate of 
hydrolysis of the corticosteroid to its active moiety.  Once in the active form, the 
corticosteroid may exert its effects at the cellular level (Trotter 1996b).   
Glucocorticoids have been shown to bind to specific glucocorticoid receptors 
present on neutrophils, monocytes, lymphocytes, and eosinophils which act to modulate 
expression of certain genes inhibiting action of inflammatory cytokines (IL-1 and NF-
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κB), thus significantly decreasing the inflammatory reaction (Boumpas, et al., 2001; 
Gilron, 2004).  Probably the most recognized effect of corticosteroids is their anti-
inflammatory action through inhibition of prostaglandin production.  Corticosteroids act 
through lipocortin-induced phospholipase inhibition preventing the mobilization of 
phospholipids within the cell membranes to become available for the arachidonic acid 
cascade, ultimately resulting in inhibition of production of prostaglandins and 
leukotrienes responsible for pain and inflammation (Di Rosa, 1985; Gilron, 2004).   
The commonly used corticosteroids for equine joint injections include 
methylprednisolone acetate (Depo-Medrol), triamcinolone acetonide (Kenalog), and 
betamethasone sodium phosphate/betamethasone acetate (Celestone Soluspan).  Several 
studies, both in vitro and in vivo, have been performed looking at the beneficial and 
detrimental effects of these corticosteroids on the articular cartilage (Dechant, et al., 
2003; Doyle, et al., 2005; Foland, et al., 1994; Frisbie, et al., 1997; Frisbie, et al., 1998; 
Fubini, et al., 2001; MacLeod, et al., 1998; Murphy, et al., 2000; Roneus, et al., 1993; 
Sandler, et al., 2004; Shoemaker, et al., 1992; Todhunter, et al., 1993; Todhunter, et al., 
1996; Trotter, et al., 1991; Tulamo 1991; Yates, et al., 2006).  Of these three 
corticosteroids, methylprednisolone has the longest duration of action against 
inflammation associated with osteoarthritis, followed by betamethasone and then 
triamcinolone (Frisbie, 2006).  Detrimental effects of methylprednisolone include 
decreased proteoglycan synthesis, increased proteoglycan degradation, decreased mRNA 
expression of collagen type II and aggrecan, and articular cartilage erosion (Doyle, et al., 
2005; Murphy, et al., 2000; Todhunter, et al., 1996; Yates, et al., 2006; Frisbie, et al., 
1998).  However, at lower physiologic doses, methylprednisolone has been shown to 
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exert some protective effects (Farquhar, et al., 1996; Murphy, et al., 2000; Todhunter, et 
al., 1996).  In contrast, triamcinolone has been demonstrated to have mostly beneficial 
effects on articular cartilage (Frisbie, et al., 1997; Sandler, et al., 2004; Dechant, et al., 
2003).  An in vivo study showed triamcinolone minimized the development of secondary 
osteoarthritis in an osteochondral fragment model (Frisbie, et al., 1997).  A recent in vitro 
study demonstrated that triamcinolone may inhibit degradative enzymes, such as matrix 
metalloproteinases, while protecting gene transcription of extracellular matrix factors 
(Richardson, et al., 2003).  Both in vitro and in vivo work evaluating these corticosteroids 
would indicate that triamcinolone is best recommended for intra-articular use, especially 
in high-motion joints (Frisbie, 2006). 
 
2.3.2 Hyaluronic Acid 
 Hyaluronic acid is a polyanionic nonsulfated glycosaminoglycan consisting of 
repeating disaccharide units of D-glucoronic acid and N-acetylglucosamine in a long 
unbranched chain, forming particles of widely varying sizes (Howard, et al., 1993).  The 
molecular weight of hyaluronic acid measured in synovial fluid has been reported in the 
range of 0.5 to 3.0 million daltons (Tew, 1984; Tulamo, et al., 1994).  However, the 
maximal limit for molecular mass determination using the high-performance liquid 
chromatography-gel exclusion chromatography technique was 3 million daltons, leaving 
open the possibility of much higher molecular weight hyaluronic acid molecules within 
the synovial fluid and extracellular matrix (Tulamo, et al., 1994).  Hyaluronate 
concentrations within the synovial fluid can vary within one individual depending on 
various joints, with smaller joints generally having a higher concentration (Auer, et al., 
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1980).  Hyaluronate concentrations in normal equine synovial fluid range from 0.33 to 
1.5 mg/mL depending on the technique used to quantify the amount (Howard, et al. 
1993).  The half-life of exogenous hyaluronic acid injected into normal equine joints has 
been estimated around 96 hours (Hilbert, et al., 1985).  Conversely, half-life of 
exogenous hyaluronic acid and its clearance from the joint are significantly reduced in 
diseased joints (Fraser, et al., 1993). 
 The specific mechanism of action of hyaluronic acid is unknown.  However, it has 
been theorized that exogenous hyaluronate preparations supplement the actions of 
depleted or depolymerized endogenous hyaluronate in the synovial fluid, and results in 
restoration of viscoelasticity, steric hindrance and lubrication of the synovium (Howard, 
et al., 1993).  Anti-inflammatory effects of hyaluronate have also been demonstrated.  In 
vitro studies have shown reduction of macrophage chemotaxis and phagocytosis and 
decreased proliferation and migration of lymphocytes (Balazs, et al., 1985; Forrester, et 
al., 1981; Swanstrom, 1978).  Hyaluronate has also been shown to inhibit neutrophil-
mediated degradation of articular cartilage through decreased release of sulfated 
glycosaminoglycans (Tobetto, et al., 1994).  An intravenous preparation of hyaluronic 
acid was evaluated in horses with experimentally induced osteochondral fragments and 
found to reduce clinical lameness, reduce articular cartilage thinning and fibrillation, and 
reduce levels of intra-articular prostaglandins when compared with the saline treated 
group (Kawcak, et al., 1997).  However, it remains uncertain if hyaluronic acid acts only 
by inhibitory effects on inflammation or if there is a secondary chondroprotective 
mechanism (Howard, et al., 1993).   
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 There is still much debate over the importance of molecular weight in the efficacy 
of exogenous hyaluronic acid therapy.  Aviad et al. postulated that the beneficial effects 
of hyaluronic acid were due to its pharmacological properties of cellular modulation 
rather than the physical properties, such as molecular weight (Aviad, et al., 1994).  A 
clinical study evaluated a low molecular weight hyaluronate versus a high molecular 
weight product in racing Thoroughbreds with carpitis and showed no clinically 
significant differences between the two treatments (Aviad et al., 1988).  A met analysis 
study concluded that medium molecular weight hyaluronic preparations demonstrated the 
most beneficial effects by restoring rheological properties of the synovial fluid and 
reducing indices of synovial inflammation (Ghosh, et al., 2002).  Conversely, an in vitro 
study by Smith et al. demonstrated that hyaluronic acid with a molecular weight of 
greater than 5x105 daltons stimulated the synthesis of hyaluronate in a dose-dependent 
manner, while hyaluronic acid preparations less than 5x105 daltons had little or no effect 
except at high concentrations where synthesis was still depressed (Smith, et al., 1987).  A 
comparative study of five different hyaluronic acid preparations in racehorses with 
traumatic arthritis was performed and demonstrated longer duration of soundness with 
preparations of molecular weights of 2x106 daltons or greater (Phillips, 1989).  More 
recent studies have further documented the beneficial effects of high molecular weight 
hyaluronic acid preparations on the articular chondrocytes through inhibition of 
phagocytosis and migration, restoration of mean molecular weight levels to levels 
obtained prior to induction of carpitis, and inhibition of PGE2 production. (Forrester, et 
al., 1980; Akatsuko, et al., 1993; White, et al., 1999; Campo, et al., 2009).   
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2.3.3 Combination Treatment 
 The use of hyaluronic acid in combination with corticosteroids has become a 
popular therapeutic approach by many clinicians.  However, scientific evidence to 
support the combination therapy is minimal.  One of the first reports of combination 
therapy concluded that the grouping of hyaluronic acid with a corticosteroid resulted in 
better and longer lasting improvement in lameness than corticosteroids alone (Rydell, et 
al., 1970).  Another study suggested that combination of hyaluronic acid with either 
methylprednisolone or betamethasone mitigated the deleterious effects of biochemical 
degradation seen with repeated corticosteroid injections (Roneus, et al., 1993).  More 
recent studies looked at the effects of a medium-molecular weight hyaluronic acid in 
combination with methylprednisolone both on normal cartilage explants and IL-1 induced 
chondrocyte pellets (Doyle, et al., 2005; Yates, et al., 2006).  These studies concluded 
that there was no beneficial effect of combination therapy on normal cartilage explants, 
and hyaluronic acid treatment did little to mitigate the proteoglycan catabolism caused by 
corticosteroid treatment (Doyle, et al., 2005).  However, there was a beneficial effect on 
proteoglycan metabolism in the combination therapy when the treatments were applied to 
chondrocytes that were exposed to IL-1. (Yates, et al., 2006).  The purpose of this study 
was to evaluate the effects of two of the most commonly used intra-articular therapies in 
high motion joints.  This included a medium-acting corticosteroid (triamcinolone) and a 
high molecular weight hyaluronic acid (Hylartin-V).  Our hypothesis was that 
administration of hyaluronic acid alone or in combination with triamcinolone would 
mitigate the chondrocyte proteoglycan catabolism caused by IL-1 administration. 
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CHAPTER 3. MATERIALS AND METHODS 
3.1 Pellet Culture 
All horses used in this study were euthanized by a lethal dose of sodium 
pentobarbital administered intravenously for reasons unrelated to joint disease.  The 
Institutional Animal Care and Use Committee at the University of Illinois approved this 
study.  Articular cartilage was aseptically collected from the fetlock joints of 10 horses, 
ranging in age from 2 to 4 years.  All joints were evaluated to ensure there was no gross 
evidence of joint disease prior to cartilage collection.  The cartilage was placed in 
chondrogenic media consisting of Dulbecco modified Eagle medium,a 10% fetal bovine 
serum,b 1% L-glutamine,c 1% penicillin-streptomycin,d and ascorbic acid (50 µg/mL),e 
and digested overnight with 0.2% collagenase.f  After digestion, an estimation of total 
chondrocyte number and viability was made using a Reichart hematocytometer and 
Trypan blue stain.g  The chondrocytes were resuspended at a concentration of 500,000 
cells/mL in chondrogenic media.  The media containing the chondrocytes was transferred 
to Eppendorf tubes (0.5mL/tube).  The media was centrifuged to form chondrocyte 
pellets containing 250,000 cells.  The pellets were incubated at 37ºC for 7 days to allow 
formation of an extracellular matrix and the media was changed every 2 to 3 days. 
Treatments were administered on day 7 and the pellets were incubated for an 
additional 24 hours.  There were 10 treatment groups with a minimum of 10 pellets in 
each group.  Treatment groups (Table 1) consisted of fresh media only (negative control), 
fresh media with 10 ng/mL of IL-1h only (positive control), IL-1 (10 ng/mL) and HAi 
(0.5 mg/mL or 2 mg/mL; 2 treatment groups), IL-1 (10 ng/mL) and TAj (0.06 mg/mL or 
0.6 mg/mL; 2 treatment groups), and IL-1 (10 ng/mL) with both HA (0.5 mg/mL or 2 
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mg/mL) and TA (0.06 mg/mL or 0.6 mg/mL; 4 treatment groups).  The concentrations of 
HA and TA were determined from a range of published concentrations likely to be 
present in the fetlock joint 24 to 48 hours after an intra-articular injection (Chen, et al., 
1992; Hilbert, et al., 1985).  At the time of treatment, 4 pellets from each treatment group 
were radiolabeled with media containing sulfur 35 (S35)-labeled sodium sulfate (10 
µCi/mL).k  All pellets were removed from the treatment media after 24 hours of 
incubation and were washed 3 times with PBS solution.  Seven horses had 4 radiolabeled 
pellets and exhausted media stored at -80ºC until further analysis.  Three horses had 20 
pellets in each treatment group snap frozen in liquid nitrogen and saved at -80ºC for RNA 
isolation.  Six horses had 2 pellets per treatment group saved for histological 
examination. 
3.2 Proteoglycan Synthesis 
 New proteoglycan synthesis was determined by 35SO4 incorporation into the pellet 
content and subsequent release into the media over a 24 hour period.  Radiolabeled 
pellets were digested in papain (150 µg/mL)l at 65ºC for 24 hours.  Radiolabeled media 
was digested in papain (150 µg/mL) at 65ºC for 4 hours.  Aliquots of 25 µL radiolabeled 
papain-digested pellets and 25 µL radiolabeled papain-digested media were placed in 96-
well MultiScreen filtration plates,m precipitated with 0.2% Alcian blue dye solution, and 
counted for scintillation (Masuda, et al., 1994).  Radio-isotope decay was accounted for 
in all values. 
3.3 Total Pellet GAG Content 
 Total GAG content in the pellets and in the media was determined using a 
dimethylmethylene blue binding assay (Farndale, et al., 1982).  Pellets were digested in 
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papain as described previously.  Aliquots of 25 µL papain-digested pellets were placed 
into 96-well microplates, 200 µL of 1,9-Dimethylmethylene Blue dyen was added, and 
samples were analyzed for absorbance.  All samples were compared against a standard 
curve of chondroitin sulfate to estimate the total GAG content of the digested pellets. 
3.4 Total Pellet DNA Content 
 Total DNA content of each pellet was determined using a fluorometric Hoechst 
assay (Kim, et al., 1988).  Pellets were digested in papain as described previously.  
Aliquots of 10 µL papain-digested pellets were placed into 96-well microplates, 200 µL 
of Hoechst dye solutiono was added, and samples were analyzed for fluorescence in a 
microplate reader.p  All samples were compared against a standard curve of calf thymus 
to estimate total DNA content of the digested pellets. 
3.5 Pellet mRNA Levels 
 Real-time PCR data was obtained from chondrocyte pellet cultures of 3 horses.  
The RNA was extracted from 20 pellets in each treatment group per horse using the 
Trizol reagentq according to the manufacturer’s suggested protocol.  Complementary 
DNA was obtained by priming the sample with oligo d(T)r and then adding reverse 
transcriptase.s  Real-time quantitative PCR analysis was performed for collagen type II, 
aggrecan, and COX-2, and normalized to elongation factor-1α mRNA expression.  A 
PCR detection systemt was used to perform the assay (Doyle, et al., 2005; Yates, et al., 
2006; Livak and Schmittgen, 2001). 
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3.6 Histologic Examination 
 After 24 hours in 4% paraformaldehyde, pellets were transferred to a 4% agarose 
gel and stored at 4ºC overnight.  The pellets were dehydrated in alcohol, embedded in 
paraffin, sectioned, and stained with Toluidine blue. 
3.7 Statistical Analysis 
 All non-normally distributed data were logarithmically transformed and presented 
as mean ± SE log values.  Significance of IL-1 was determined by using a one-way 
repeated-measures ANOVA generated through the SigmaStatu software program 
comparing the positive control (IL-1) to the negative control (no IL-1).  Significance of 
HA and TA was determined using a two-way repeated-measures ANOVA generated 
through the SigmaStatu software program.  All post hoc tests were conducted when 
indicated by use of the Holm-Sidak method.  Values of  P ≤ 0.05 were considered 
significant. 
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0.621010
0.60.5109
0.60108
0.062107
0.060.5106
0.060105
02104
00.5103
00102 (positive control)
0001 (negative control)
TA 
mg/mL
HA 
mg/mL
IL-1 
ng/mL
Treatment Group
10 Horses
7 Horses
PG synthesis
Pellet GAG
Pellet DNA
Histology (6/7)
3 Horses
RNA analysis
 
Table 1.  Treatment Groups Chondrocytes were collected from 10 horses.  Each horse 
was run as a separate experiment.  All experiments had the same 10 treatment groups.  
Seven horses were collected for PG synthesis, pellet GAG content, and pellet DNA 
content.  Only 6 of these 7 horses were evaluated histologically.  Three horses were 
collected for RNA analysis. 
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CHAPTER 4. RESULTS 
 
4.1 Pellet GAG Synthesis 
 Pellet GAG synthesis was designated as the amount of newly synthesized GAG 
retained in the pellet (CPM per chondrocyte pellet).  Treatment with IL-1 significantly (P 
= 0.018) decreased GAG synthesis in the positive control (IL-1 only) when compared to 
the negative control (no IL-1; Figure 1).  Treatment with HA (2 mg/mL) significantly (P 
< 0.001) increased GAG synthesis when compared to the IL-1 control group.  The 0.006 
and 0.6 mg/mL TA treatment groups did not have a significant (P = 0.218) effect on 
GAG synthesis when compared to the 0 mg/mL TA treatment group.  However, there 
was a significant (P = 0.004) interaction with the combined treatment of HA and TA on 
increasing GAG synthesis.  Specifically, 2 mg/mL of HA combined with 0.06 or 0.6 
mg/mL of TA significantly increased GAG synthesis compared to the IL-1 control group. 
4.2 Total GAG Synthesis 
 Total GAG synthesis was designated as the amount of newly synthesized GAG 
retained in the pellet and released into the media (CPM pre chondrocyte pellet + CPM per 
media).  Treatment with IL-1 showed no significant (P = 0.097) difference in total GAG 
synthesis when the positive control (IL-1 only) was compared to the negative control (no 
IL-1; Figure 2).  Treatment with HA (2 mg/mL) showed a significant (P = 0.026) 
increase in total GAG synthesis when compared to the IL-1 control group.  Treatment 
with TA did not show a significant (P = 0.607) effect on total GAG synthesis.  There was 
no significant (P = 0.48) interaction with HA and TA combined on total GAG synthesis. 
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4.3 Percent GAG Retained in the Pellet and Released into the Media 
 Percent GAG retained in the pellet was designated as the percentage of newly 
synthesized GAG retained in the pellet (CPM per pellet/[CPM per pellet + CPM per 
media]).  Percent GAG released into the media was designated as the percentage of 
newly synthesized GAG released into the media (CPM pre media/[CPM per pellet + 
CPM per media]).  Treatment with IL-1 significantly (P = 0.04) decreased the percent 
GAG retained within the pellets and significantly (P = 0.04) increased the percent GAG 
released into the media when the positive control (IL-1 only) was compared to the 
negative control (no IL-1; Figure 3, Figure 4).  Treatment with HA did not have a 
significant (P = 0.26) effect on percent GAG retained within the pellet or on the percent 
GAG released into the media (P = 0.26) when compared to the IL-1 control group.  
Treatment with TA showed a significant (P = 0.004) increase in percent retention of 
newly synthesized GAG within the pellet and a significant (P = 0.004) decrease in 
percent newly synthesized GAG released into the media.  Specifically, the 0.06 and 0.6 
mg/mL TA groups had a significant increase in percent GAG retained within the pellets 
and a significant decrease in percent GAG released into the media when compared to the 
0 mg/mL TA treatment group.  There was no significant (P = 0.67) interaction with HA 
and TA combined on percent GAG retained in the pellet of percent GAG released into 
the media. 
4.4 Total GAG Pellet Content 
  Total pellet GAG content was designated as the total GAG content retained in the 
pellet after treatment and this included the newly synthesized GAG (µg per chondrocyte 
pellet).  Treatment with IL-1 did not have a significant (P = 0.101) effect on the total 
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pellet GAG content when the positive control (IL-1 only) was compared to the negative 
control (no IL-1; Figure 5).  Treatment with HA (2 mg/mL) significantly (P = 0.002) 
increased the total GAG content within the pellet when compared to the IL-1 control 
group.  Treatment with TA (0.6mg/mL) significantly (P = 0.036) increased total GAG 
pellet content when compared to the 0 mg/mL TA treatment group.  There was no 
significant (P = 0.732) interaction with HA and TA combined on the total GAG pellet 
content. 
4.5 Total DNA pellet content 
 Total DNA pellet content was designated as the total amount of DNA per pellet 
(µg per pellet).  Treatment with IL-1 (P = 0.217), HA (P= 0.781), or TA (P = 0.982) had 
no significant effect on the total DNA content per pellet. 
4.6 Pellet mRNA Levels 
 Treatment with IL-1 significantly (P = 0.026) increased collagen type II mRNA 
levels when the positive control (IL-1) was compared to the negative control (no IL-1; 
Figure 6).  Treatment with HA had no significant (P = 0.102) effect on collagen type II 
mRNA levels when compared to the IL-1 control group.  Treatment with 0.06 and 0.6 
mg/mL TA significantly (P = 0.001) decreased collagen type II mRNA levels when 
compared to the IL-1 control group.  There was no significant (P = 0.121) interaction of 
HA and TA combined on collagen type II mRNA levels. 
 Treatment with IL-1 significantly (P = 0.045) increased aggrecan mRNA levels 
when the positive control (IL-1) was compared to the negative control (no IL-1; Figure 
7).  Treatment with HA did not have a significant (P = 0.725) effect on aggrecan mRNA 
levels when compared to the IL-1 control group.  Treatment with TA had a significant (P 
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= 0.045) effect upon aggrecan mRNA levels.  Specifically, the 0.06 and 0.6 mg/mL TA 
treatment groups significantly decreased aggrecan mRNA levels when compared to the 
IL-1 control group.  There was no significant (P = 0.11) interaction of HA and TA 
combined on aggrecan mRNA levels. 
 Treatment with IL-1 significantly (P = 0.021) increased COX-1 mRNA levels 
when the positive control group (IL-1) was compared to the negative control (no IL-1; 
Figure 8).  Treatment with HA did not have a significant (P = 0.126) effect on COX-2 
mRNA levels when compared to the IL-1 control group.  Treatment with TA had a 
significant (P = 0.007) effect on COX-2 mRNA levels.  Specifically, the 0.06 and 0.6 
mg/mL TA treatment groups significantly decreased COX-2 mRNA levels when 
compared to the IL-1 control group.  There was no significant (P = 0.464) interaction of 
HA and TA combined on COX-2 mRNA levels. 
4.7 Histologic Examination 
 The chondrocyte pellets varied in size dependent on the horse.  The size of the 
pellets was not measured; instead the pellets were only evaluated for proteoglycan 
production through use of the toluidine blue stain.  Subjective pellets treated with HA, 
TA, or the combination of HA and TA, had increased proteoglycan staining throughout 
the pellet matrix (Figure 9). 
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Figure 1. Pellet GAG Synthesis – Log mean ± SE incorporation of sulfur 35-labeled 
sodium sulfate into GAG of equine articular chondrocyte pellets treated with various 
concentrations of HA and TA.  Scintillation counts (counts per minute [CPM]) were 
normalized for decay and pellet digestion volume. *Significant (P < 0.05) difference 
between negative control (no IL-1) and positive control (IL-1 only).  †Significant (P < 
0.05) effect of HA compared with no HA at the same concentrations of TA.  ‡Significant 
(P < 0.05) effect of combination therapy (HA and TA) compared to the IL-1 control. 
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Figure 2. Total GAG Synthesis - Log mean ± SE incorporation of sulfur 35-labeled 
sodium sulfate into GAG of both equine articular chondrocyte pellets and the media 
following treatment with various concentrations of HA and TA.  Scintillation counts 
(counts per minute [CPM]) were normalized for decay and pellet digestion volume.  
*Significant (P < 0.05) effect of HA compared with no HA at the same concentrations of 
TA. 
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Figure 3. Percent GAG Retained in the Pellet - Percent mean ± SE incorporation of 
sulfur 35-labeled sodium sulfate into GAG of equine articular chondrocyte pellets treated 
with various concentrations of HA and TA.  Scintillation counts (counts per minute 
[CPM]) were normalized for decay and pellet digestion volume.  *Significant (P < 0.05) 
difference between negative control (no IL-1) and positive control (IL-1 only).  
†Significant (P < 0.05) effect of TA treatment groups compared with the no TA treatment 
group at all concentrations of HA. 
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Figure 4. Percent GAG Released into the Media - Percent mean ± SE incorporation of 
sulfur 35-labeled sodium sulfate into GAG released into media following treatment with 
various concentrations of HA and TA.  Scintillation counts (counts per minute [CPM]) 
were normalized for decay and pellet digestion volume.  *Significant (P < 0.05) 
difference between negative control (no IL-1) and positive control (IL-1 only).  
†Significant (P < 0.05) effect of TA treatment groups compared with the no TA treatment 
group at all concentrations of HA. 
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Figure 5. Total GAG Pellet Content - Log mean ± SE total GAG content in equine 
articular chondrocyte pellets treated with various concentrations of HA and TA.  Content 
of GAG was normalized for pellet digestion volume.  *Significant (P < 0.05) effect of 
HA compared with no HA at the same concentrations of TA.  †Significant (P < 0.05) 
effect of TA treatment groups compared with the no TA treatment group at all 
concentrations of HA. 
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Figure 6. Collagen Type II mRNA Levels -  Mean ± SE collagen type II mRNA levels 
in equine articular chondrocyte pellets treated with various concentrations of HA and TA.  
Collagen type II mRNA levels were normalized to elongation factor 1-α mRNA levels.  
*Significant (P < 0.05) difference between negative control (no IL-1) and positive control 
(IL-1 only).  †Significant (P < 0.05) effect of TA treatment groups compared with the no 
TA treatment group at all concentrations of HA. 
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Figure 7. Aggrecan mRNA Levels - Mean ± SE aggrecan mRNA levels in equine 
articular chondrocyte pellets treated with various concentrations of HA and TA.  
Aggrecan mRNA levels were normalized to elongation factor 1-α mRNA levels.  
*Significant (P < 0.05) difference between negative control (no IL-1) and positive control 
(IL-1 only).  †Significant (P < 0.05) effect of TA treatment groups compared with the no 
TA treatment group at all concentrations of HA. 
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Figure 8. COX-2 mRNA Levels - Mean ± SE COX-2 mRNA levels in equine articular 
chondrocyte pellets treated with various concentrations of HA and TA.  COX-2 mRNA 
levels were normalized to elongation factor 1-α mRNA levels.  *Significant (P < 0.05) 
difference between negative control (no IL-1) and positive control (IL-1 only).  
†Significant (P < 0.05) effect of TA treatment groups compared with the no TA treatment 
group at all concentrations of HA. 
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Figure 9. Histologic Examination - Photomicrographs at 40X magnification of sections 
of equine articular chondrocyte pellets obtained 24 hours after administration of IL-1 
treatment, 2 mg/mL HA, 0.6 mg/mL TA, or 2 mg/mL HA and 0.6 mg/mL TA.  Toluidine 
blue stain; bar = 100 µm. 
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CHAPTER 5. DISCUSSION 
 Results of this study demonstrated the beneficial effects of HA alone and in 
combination with TA on IL-1 treated equine articular chondrocyte pellets.  HA increased 
both the new GAG synthesis by the chondrocytes and the total GAG content retained in 
the pellets when compared to the IL-1 control.  Treatment with TA increased the total 
GAG content retained in the chondrocyte pellet.  These results are similar to another 
study where TA combated the IL-1 induced GAG degradation (Sandler, et al., 2004).  
Treatment with TA also reduced COX-2 mRNA expression when compared to the IL-1 
control.  Most of these benefits were seen at the high concentration of HA (2 mg/mL) and 
the high concentration of TA (0.6 mg/mL).  The combination of 2 mg/mL HA and 0.6 
mg/mL TA had the highest levels of total pellet GAG following treatment with IL-1. 
 Treatment with IL-1 had several detrimental effects on chondrocyte metabolism.  
Administration of IL-1 caused a decrease in GAG synthesis and retention by the pellet 
ultimately resulting in a decreased newly synthesized pellet GAG content.  Treatment 
with IL-1 also increased COX-2 mRNA expression.  In addition, IL-1 administration 
caused an increase in aggrecan and collagen type II mRNA production.  This may be due 
to an increase in chondrocyte metabolism of aggrecan and collagen type II in response to 
an IL-1 mediated matrix catabolism (MacLeod, et al., 1998). 
 Treatment with HA increased GAG synthesis and total GAG pellet content but 
did not have an effect on mRNA levels of COX-2, aggrecan, or collagen type II.  
Specifically, addition of HA (2 mg/mL) was beneficial in negating the effects of IL-1 
administration and increasing new GAG synthesis.  Lower concentrations of HA did not 
have a significant effect on GAG synthesis.  The higher concentrations of HA increased 
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incorporation of GAG side chains into the pellet matrix.  Although HA was beneficial for 
GAG synthesis, treatment with HA had no effect on COX-2 mRNA levels suggesting that 
matrix degradation continued to occur in these treatment groups.  HA also had no effect 
on collagen type II and aggrecan mRNA levels, but maintained expression rates similar to 
the IL-1 treated control group.  The disparity between the aggrecan mRNA expression 
data and the new GAG synthesis suggests that HA may have increased synthesis of 
products other than aggrecan, such as biglycan and decorin.  Alternatively, the retention 
of aggrecan in the pellet after synthesis may have been more effective in the presence of 
HA.  Ultimately, the proteoglycan synthesis, proteoglycan release, and the total GAG 
retained in the pellet matrix are probably the most important pieces of information 
obtained from this study.   
 Treatment with TA increased total pellet GAG content and decreased mRNA 
levels of COX-2, aggrecan, and collagen type II.  Specifically, treatment with TA 
increased total GAG pellet content by increasing GAG retention within the pellet while 
decreasing GAG lost into the media.  In addition, TA was beneficial in suppressing COX-
2 mRNA levels that increased with IL-1 treatment.  As seen in other studies using a 
corticosteroid, treatment with TA was effective at a cellular level in blocking mediators 
of inflammation (Yates, et al., 2006; Frisbie, et al., 1998; and Murphy, et al., 2000).  In 
this study, treatment with TA suppressed mRNA levels of aggrecan and collagen type II.  
However, the TA-treated expression levels were similar to the baseline levels expressed 
by treatment groups with no IL-1.  Corticosteroid-induced suppression of aggrecan and 
collagen type II mRNA levels has been demonstrated in previous studies (Fubini, et al., 
2001). Corticosteroid-induced suppression of aggrecan and collagen type II mRNA levels 
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may have detrimental effects in a longer term study.  These results suggest TA 
predominantly works by suppressing inflammation to retain GAG in the pellet, not by 
increasing the synthesis of GAG in the pellet. 
 Finally, combination treatment of HA and TA mitigated the effects of IL-1 
administration by increasing new GAG synthesis and retention within the pellet.  The 
high concentrations of both drugs, HA at 2 mg/mL and TA at 0.6 mg/mL, in combination 
had the most profound effect on GAG synthesis.  These results suggest that HA and TA 
mitigate the detrimental effects of IL-1 administration through different mechanisms to 
increase the total GAG content within the pellet.  In an inflammatory environment such 
as that created by IL-1 administration, high concentrations of HA may be beneficial in 
supporting chondrocyte GAG production while high concentrations of TA may act in an 
additive or synergistic fashion by retaining GAG within the chondrocyte matrix. 
 Similar to a previous study, IL-1 was administered to create an inflammatory 
environment (Yates, et al., 2006).  While IL-1 produced expected detrimental effects in 
this study, other inflammatory mediators are also known to be present in osteoarthritic 
joints.  These pro-inflammatory mediators include tumor necrosis factor-α, interleukin-6, 
interleukin-8, interleukin-11, interleukin-17, and leukemia inhibitory factor (Shi, et al., 
2004).  Several studies have documented the detrimental effects of these inflammatory 
cytokines, suggesting that they may act along different pathways or in a synergistic 
fashion with IL-1 (Shi, et al., 2004; Schuerwegh, et al., 2003).  Results of this study may 
have been amplified if other pro-inflammatory mediators had been utilized with IL-1 
administration to create a model of inflammation. 
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 This study utilized an in vitro model to study the effects of inflammation on 
cartilage metabolism.  While an in vitro study provided a controlled environment to 
evaluate the effect of multiple different concentrations of HA and TA on a standardized 
cartilage matrix, many important in vivo influences are lost.  Specifically, an in vitro 
study does not allow for clearance of metabolites from the local environment or for 
systemic metabolism of administered medications.  Therefore, these results may not 
accurately represent what would occur in an in vivo model.  Further in vitro studies 
evaluating the effects of HA and TA in equine osteoarthritic joints may provide further 
insight into the benefits and deficiencies of intra-articular HA and TA administration. 
 The range of HA and TA concentrations used in this study were based on 
estimated joint concentrations following commonly used intra-articular dosages.  In a 
previous study, TA at 1.2 mg/mL decreased IL-1 induced GAG degradation, but was 
unable to maintain GAG synthesis and showed an overall decrease in GAG synthesis 
(Sandler, et al., 2004).  In this study, the highest dose of TA (0.6 mg/mL) had a protective 
effect against IL-1 induced GAG degradation without any decline in GAG synthesis.  
Based on these findings, it is possible that TA concentrations above 0.6 mg/mL may have 
some detrimental effects on chondrocytes such as those exhibited with high doses of 
MPA (Doyle, et al., 2005; Yates et al., 2006; Sandler et al., 2004; and Dechant et al., 
2003).   
 The effects of an intermediate acting corticosteroid in this study were similar to 
results from a previous study using a similar model and a long acting corticosteroid 
(Yates, et al., 2006).  The response to corticosteroid administration was similar for pellet 
GAG synthesis, total pellet GAG content, total pellet DNA content, and mRNA 
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expression.  Both MPA and TA increased pellet GAG synthesis in combination with HA 
suggesting a significant benefit when both corticosteroids and HA are used.  Both 
corticosteroids, MPA and TA, significantly increased the total pellet GAG content.  Both 
MPA and TA had no significant effect on the total pellet DNA content.  Finally, MPA 
and TA both had a significant effect on reducing mRNA levels of COX-2 in the presence 
of IL-1 administration.  The findings of these two studies illustrate the beneficial effects 
corticosteroids have on reducing inflammation and retaining GAG content in the matrix.  
These studies also showed the combination of corticosteroids and HA had the most 
beneficial effect on increasing GAG synthesis of the pellet and retaining the total GAG 
within the pellet. 
 In this study, a high molecular weight HA (3,000,000) was used.  In previous 
studies, a medium molecular weight HA (500,000 to 730,000) showed no significant 
effects on new GAG synthesis when used alone (Doyle, et al., 2005; Yates, et al., 2006).  
In contrast, this study showed an increase in new GAG synthesis and an increase in total 
pellet GAG content with only HA administration at 2 mg/mL.  These results suggest that 
a high molecular weight HA may be more beneficial in mitigating IL-1 induced 
proteoglycan catabolism.  However, the efficacy of different molecular weights of HA 
still remains a controversial subject that needs further conclusive in vivo evaluation 
(White, et al., 1999; Phillips, 1980; and Gosh and Guidolin, 2002). 
 The highest concentration of HA administered in this study, in combination with 
TA co-administration, had the most beneficial effects on mitigating IL-1’s catabolic 
actions on proteoglycan matrix metabolism.  This effect was a result of both increased 
GAG synthesis and, more importantly, an increase in retention of pellet GAG through a 
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decrease in inflammatory mediators.  Future studies may be useful to identify the specific 
inflammatory mediators and matrix-degradative enzymes responsive to IL-1 stimulation 
and to evaluate the in vivo effects of TA and a high molecular weight HA in osteoarthritic 
equine joints. 
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FOOTNOTES 
a. DMEM, Mediatech Inc, Herndon, Va. 
b. Fetal bovine serum, Gemini Bioproducts, Woodland, Calif. 
c. L-glutamine 200mM, Invitrogen, Carlsbad, Calif. 
d. Penicillin-streptomycin, BioWhittaker, Cambrex Bio Science, Walkersville, Md. 
e. Ascorbic acid, WAKO, Richmond, Va. 
f. Collagenase Type 2, Worthington Biomedical Corp, Lakewood, NJ. 
g. Trypan Blue stain, 0.4%, Invitrogen, Carlsbad, Calif. 
h. Interleukin-1, R&D Systems, Minneapolis, Minn. 
i. Hylartin-V, Pfizer Inc, New York, NY. 
j. Vetalog, Fort Dodge Laboratories, Fort Dodge, Iowa. 
k. S-35-labeled sodium sulfate, MP Biochemicals, Irvine, Calif. 
l. Papain, Sigma-Aldrich, St Louis, Mo. 
m. Multiwell punch plates, PDVF plate, Millipore, Bedford, Mass. 
n. 1,9-Dimethyl-Methylene Blue, Sigma-Aldrich, St Louis, Mo. 
o. Hoechst 33258, Sigma-Aldrich, St Louis, Mo. 
p. Microplate reader, FLUOstar Optima, BMG Laboratories, Durham, NC. 
q. Trizol, Invitrogen, Carlsbad, Calif. 
r. Oligo d(T), Invitrogen, Carlsbad, Calif. 
s. Superscript II, Invitrogen, Carlsbad, Calif. 
t. iCycler iQ real-time PCR detection system, BioRad Laboratories, Hercules, Calif. 
u. SigmaStat, version 3.0, Systat Software Inc, San Jose, Calif. 
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5685 
6107 
 
13541 
7673 
10157 
8645 
7863 
5578 
4847 
4147 
4285 
5278 
6713 
 
 
3817 
3812 
3822 
4121 
4305 
4407 
3819 
4057 
2407 
2967 
1503 
1988 
2335 
3287 
1856 
2064 
6882 
7218 
5897 
6395 
7223 
7550 
4139 
4263 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5213 
 
4216 
 
5995 
 
 
 
3815 
 
3972 
 
4356 
 
3938 
 
2687 
 
1745 
 
2811 
 
1960 
 
7050 
 
6146 
 
7386 
 
4201 
 
8134 
7721 
8041 
8840 
5434 
6213 
5825 
6257 
 
13874 
7862 
10407 
8857 
8057 
5779 
 
4674 
 
6647 
 
 
 
4229 
 
4403 
 
4829 
 
4366 
 
2979 
 
1935 
 
3116 
 
2173 
 
7816 
 
6814 
 
8189 
 
4658 
 
32538 
30886 
32164 
35362 
21737 
24852 
23301 
25301 
 
55499 
31449 
41628 
35430 
32229 
23117 
 
18698 
 
26588 
 
 
 
16919 
 
17614 
 
19319 
 
17466 
 
11916 
 
7742 
 
12467 
 
8695 
 
31265 
 
27258 
 
32758 
 
18633 
 
 
 
28529 
 
 
 
34610 
 
 
 
35184 
 
 
 
22801 
 
 
 
 
 
 
 
17829 
 
 
 
 
 
 
 
10205 
 
 
 
 
 
 
 
27478 
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6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
6 
6 
6 
6 
6 
6 
7 
7 
7 
7 
7 
7 
7 
7 
8 
8 
8 
8 
8 
8 
8 
8 
9 
9 
9 
9 
9 
9 
9 
9 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
6361 
7365 
8908 
7357 
4147 
6686 
5437 
5822 
4022 
3390 
4491 
2735 
4243 
3897 
4165 
5044 
4516 
4650 
3950 
4125 
4585 
4926 
7690 
8091 
8928 
10663 
6360 
5878 
6555 
7162 
6874 
6899 
5298 
5944 
5995 
6857 
1736 
1570 
5516 
5929 
5946 
7055 
4205 
4339 
5739 
5968 
6863 
 
8133 
 
5417 
 
5629 
 
3706 
 
3613 
 
4070 
 
4605 
 
4583 
 
4037 
 
4756 
 
7890 
 
9795 
 
6119 
 
6859 
 
6886 
 
5621 
 
6426 
 
1653 
 
5723 
 
6500 
 
4272 
 
5854 
 
7609 
 
9016 
 
6005 
 
6241 
 
4108 
 
4005 
 
4512 
 
5105 
 
5081 
 
4476 
 
5272 
 
8747 
 
10860 
 
6784 
 
7604 
 
7635 
 
6232 
 
7124 
 
1833 
 
6345 
 
7207 
 
4736 
 
6490 
 
30436 
 
36067 
 
24022 
 
24966 
 
16435 
 
16022 
 
18051 
 
20421 
 
20326 
 
17906 
 
21091 
 
34991 
 
43440 
 
27137 
 
30418 
 
30540 
 
24928 
 
28498 
 
7332 
 
25380 
 
28829 
 
18946 
 
25960 
 
28873 
 
 
 
 
 
 
 
17732 
 
 
 
 
 
 
 
23579 
 
 
 
 
 
 
 
32884 
 
 
 
 
 
 
 
21534 
 
 
 
 
 
 
 
24671 
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6 
6 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
 
 
 
 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
 
 
 
 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
 
 
 
 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
 
 
 
 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
 
 
 
 
5656 
5595 
6000 
3247 
3898 
2564 
2118 
3438 
2060 
2115 
1856 
1950 
5658 
2951 
3055 
3765 
2450 
9184 
5569 
4927 
2861 
6230 
3151 
3966 
4610 
3775 
3167 
5335 
2494 
3791 
2862 
2769 
2346 
 
2664 
2867 
5409 
3509 
6399 
3393 
3750 
3568 
 
 
 
 
5625 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6237 
 
6191 
3350 
4022 
2646 
2185 
3548 
2126 
2182 
1915 
2012 
5839 
3045 
3152 
3885 
2528 
9478 
5747 
5085 
2953 
6429 
3251 
4093 
4758 
3896 
3269 
5506 
2574 
3912 
2954 
2858 
2421 
 
2749 
2959 
5582 
3621 
6604 
3502 
3870 
3683 
 
 
 
 
24948 
 
24767 
13403 
16091 
10584 
8743 
14192 
8504 
8731 
7662 
8050 
23359 
12183 
12611 
15543 
10114 
37915 
22988 
20342 
11812 
25718 
13007 
16372 
19032 
15584 
13077 
22025 
10298 
15650 
11816 
11432 
9685 
 
10999 
11838 
22330 
14485 
26416 
14009 
15483 
14732 
 
 
 
 
 
 
16211 
 
 
 
10042 
 
 
 
12813 
 
 
 
19046 
 
 
 
20215 
 
 
 
15999 
 
 
 
15262 
 
 
 
10977 
 
 
 
14913 
 
 
 
17660 
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APPENDIX B. ALCIAN BLUE MEDIA DATA
A 
Horse 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
Tx 
Group 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
IL-1 
ug/mL 
0 
0 
0 
0 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
HA 
mg/mL 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
TA 
mg/mL 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
Raw 
Data 
2601 
2541 
2772 
2721 
2112 
2148 
3012 
2981 
2444 
2347 
1736 
1388 
2318 
2095 
1787 
1564 
 
 
 
 
 
 
 
 
1420 
1532 
775 
721 
1244 
791 
1424 
2211 
4360 
3869 
4487 
2790 
2228 
1743 
1633 
2002 
 
 
Avg for 
replicate 
2571 
 
2746 
 
2130 
 
2996 
 
2395 
 
1562 
 
2207 
 
1674 
 
 
 
 
 
 
 
 
 
1476 
 
748 
 
1017 
 
1818 
 
4115 
 
3638 
 
1985 
 
1817 
 
 
 
Convert 
Decay 
2613 
 
2791 
 
2164 
 
3045 
 
2434 
 
1587 
 
2242 
 
1701 
 
 
 
 
 
 
 
 
 
1500 
 
760 
 
1034 
 
1847 
 
4182 
 
3698 
 
2018 
 
1847 
 
 
 
Total 
Media 
52260 
 
55828 
 
43297 
 
60912 
 
48696 
 
31755 
 
44859 
 
34037 
 
 
 
 
 
 
 
 
 
30006 
 
15207 
 
20686 
 
36951 
 
83642 
 
73963 
 
40363 
 
36947 
 
 
 
Avg for 
tx group 
26537 
 
 
 
 
 
 
 
19918 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12856 
 
 
 
 
 
 
 
29364 
 
 
 
 
 
 
 
 
 
 79 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
6 
6 
6 
6 
6 
6 
7 
7 
7 
7 
7 
7 
7 
7 
8 
8 
8 
8 
8 
8 
8 
8 
9 
9 
9 
9 
9 
9 
9 
9 
10 
10 
10 
10 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
 
 
 
 
 
 
1692 
1126 
2623 
2392 
1042 
1156 
6090 
2524 
1375 
1719 
1699 
2275 
2009 
1933 
1213 
1445 
 
 
 
 
 
 
 
 
445 
367 
4647 
3591 
1831 
1917 
711 
801 
446 
385 
473 
542 
275 
422 
481 
 
 
 
 
 
 
 
1409 
 
2507 
 
1099 
 
4307 
 
1547 
 
1987 
 
1971 
 
1329 
 
 
 
 
 
 
 
 
 
406 
 
4119 
 
1874 
 
756 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1432 
 
2548 
 
1117 
 
4377 
 
1572 
 
2019 
 
2003 
 
1351 
 
 
 
 
 
 
 
 
 
412 
 
4186 
 
1905 
 
769 
 
475 
410 
504 
578 
293 
450 
513 
 
 
 
 
 
 
 
28643 
 
50968 
 
22345 
 
87552 
 
31459 
 
40397 
 
40062 
 
27027 
 
 
 
 
 
 
 
 
 
8259 
 
83729 
 
38106 
 
15381 
 
9516 
8215 
10092 
11565 
5868 
9005 
10264 
 
 
 
 
 
 
 
23688 
 
 
 
 
 
 
 
17368 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18184 
 
 
 
 
 
 
 
9847 
 
 
 
8379 
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2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
3230 
 
3946 
2603 
1113 
754 
886 
 
449 
605 
763 
547 
297 
268 
254 
347 
218 
222 
820 
314 
489 
611 
310 
331 
492 
437 
383 
285 
398 
253 
401 
503 
319 
612 
506 
535 
275 
481 
215 
208 
458 
672 
464 
549 
432 
373 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3444 
 
4207 
2775 
1186 
803 
945 
 
479 
645 
814 
583 
317 
286 
271 
370 
232 
236 
874 
335 
521 
652 
330 
353 
525 
466 
408 
304 
424 
270 
427 
536 
327 
627 
518 
548 
282 
493 
220 
213 
469 
689 
475 
563 
443 
382 
68886 
 
84146 
55507 
23731 
16077 
18909 
 
9584 
12914 
16287 
11676 
6340 
5721 
5422 
7407 
4654 
4739 
17485 
6703 
10436 
13040 
6616 
7064 
10501 
9327 
8174 
6083 
8495 
5400 
8559 
10737 
6542 
12551 
10377 
10972 
5640 
9865 
4409 
4266 
9394 
13783 
9517 
11261 
8861 
7651 
69513 
 
 
 
19572 
 
 
 
12615 
 
 
 
6222 
 
 
 
8395 
 
 
 
9289 
 
 
 
8521 
 
 
 
8298 
 
 
 
10111 
 
 
 
6045 
 
 
 
10989 
 
 
 
8779 
 
 81 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
479 
 
225 
211 
131 
199 
800 
608 
302 
453 
534 
776 
851 
426 
318 
239 
246 
247 
539 
 
559 
516 
548 
356 
633 
375 
731 
861 
775 
981 
625 
1068 
542 
1771 
1780 
692 
617 
758 
1496 
1630 
2492 
2483 
683 
748 
585 
600 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
491 
 
230 
216 
134 
204 
819 
623 
309 
464 
547 
795 
872 
437 
326 
245 
252 
253 
552 
 
573 
529 
562 
365 
649 
384 
785 
924 
832 
1053 
671 
1147 
582 
1902 
1912 
743 
662 
814 
1606 
1750 
2676 
2667 
733 
803 
628 
644 
9825 
 
4616 
4329 
2687 
4082 
16394 
12475 
6196 
9295 
10957 
15903 
17442 
8741 
6523 
4902 
5046 
5067 
11057 
 
11468 
10586 
11243 
7303 
12987 
7693 
3140 
3699 
3329 
4214 
2685 
4588 
2328 
7609 
7648 
2973 
2651 
3257 
6427 
7003 
10707 
10669 
2935 
3214 
2513 
2578 
 
 
3929 
 
 
 
11090 
 
 
 
13261 
 
 
 
5384 
 
 
 
11037 
 
 
 
9807 
 
 
 
3596 
 
 
 
4303 
 
 
 
4132 
 
 
 
8702 
 
 
 
2810 
 
 
 
 82 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
368 
409 
423 
455 
2042 
1894 
755 
849 
604 
 
864 
434 
534 
572 
406 
529 
914 
1549 
1300 
3023 
817 
751 
1990 
878 
625 
603 
881 
563 
720 
1095 
591 
859 
2642 
1865 
1186 
5190 
1086 
1098 
1102 
1199 
1421 
1037 
1008 
1494 
4466 
2494 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
395 
439 
454 
488 
2193 
2034 
811 
912 
648 
 
928 
466 
573 
614 
436 
568 
981 
1664 
1396 
3247 
837 
769 
2039 
899 
640 
618 
903 
577 
738 
1122 
605 
880 
2707 
1911 
1215 
5318 
1113 
1125 
1129 
1229 
1456 
1063 
1033 
1530 
4576 
2555 
1581 
1757 
1818 
1955 
8775 
8139 
3244 
3648 
2595 
 
3712 
1865 
2294 
2548 
1744 
2273 
3927 
6656 
5586 
12991 
3349 
3079 
8158 
3599 
2562 
2472 
3612 
2308 
2952 
4489 
2423 
3522 
10828 
7646 
4862 
21272 
4453 
4502 
4518 
4916 
5827 
4252 
4134 
6123 
18307 
10223 
1778 
 
 
 
5952 
 
 
 
2724 
 
 
 
2192 
 
 
 
7290 
 
 
 
4546 
 
 
 
2738 
 
 
 
3346 
 
 
 
11152 
 
 
 
4597 
 
 
 
5084 
 
 
 
14994 
 
 83 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
3351 
4321 
801 
783 
1017 
865 
962 
1019 
989 
804 
3831 
1987 
2603 
1949 
947 
1016 
815 
1024 
1315 
1245 
1412 
706 
702 
770 
1009 
1473 
976 
1206 
1183 
860 
539 
688 
647 
892 
390 
377 
481 
671 
696 
817 
1832 
1955 
806 
961 
1953 
1917 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
982 
 
920 
 
1280 
 
1059 
 
736 
 
1241 
 
1091 
 
1022 
 
613 
 
770 
 
384 
 
576 
 
757 
 
1893 
 
883 
 
1935 
 
3433 
4428 
821 
802 
1042 
886 
986 
1044 
920 
824 
3925 
2036 
2667 
1997 
1089 
 
1020 
 
1419 
 
1174 
 
816 
 
1376 
 
1210 
 
1133 
 
680 
 
853 
 
426 
 
638 
 
839 
 
2099 
 
979 
 
2145 
 
13734 
17712 
3284 
3210 
4170 
3546 
3945 
4178 
3682 
3297 
15701 
8144 
10670 
7988 
4356 
 
4080 
 
5678 
 
4698 
 
3265 
 
5505 
 
4841 
 
4532 
 
2721 
 
3415 
 
1704 
 
2555 
 
3357 
 
8398 
 
3919 
 
8581 
 
 
 
3553 
 
 
 
3775 
 
 
 
10626 
 
 
 
4703 
 
 
 
 
 
 
 
4536 
 
 
 
 
 
 
 
2599 
 
 
 
 
 
 
 
6064 
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6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
6 
6 
6 
6 
6 
6 
7 
7 
7 
7 
7 
7 
7 
7 
8 
8 
8 
8 
8 
8 
8 
8 
9 
9 
9 
9 
9 
9 
9 
9 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
624 
686 
743 
577 
788 
723 
1144 
797 
517 
555 
447 
482 
469 
433 
536 
513 
1193 
1516 
354 
346 
913 
926 
782 
851 
667 
 
681 
1200 
874 
937 
979 
940 
855 
798 
609 
567 
782 
884 
137 
170 
1061 
1061 
914 
1184 
986 
968 
655 
 
660 
 
756 
 
971 
 
536 
 
464 
 
451 
 
524 
 
1355 
 
350 
 
919 
 
817 
 
667 
 
941 
 
906 
 
959 
 
827 
 
588 
 
833 
 
153 
 
1061 
 
1049 
 
977 
 
726 
 
732 
 
838 
 
1076 
 
594 
 
515 
 
500 
 
581 
 
1502 
 
388 
 
1019 
 
905 
 
739 
 
1043 
 
1004 
 
1063 
 
916 
 
652 
 
924 
 
170 
 
1176 
 
1163 
 
1083 
 
2906 
 
2929 
 
3353 
 
4307 
 
2378 
 
2060 
 
2000 
 
2327 
 
6010 
 
1555 
 
4078 
 
3623 
 
2959 
 
4173 
 
4017 
 
4255 
 
3667 
 
2609 
 
3696 
 
682 
 
4707 
 
4653 
 
4333 
 
3374 
 
 
 
 
 
 
 
2191 
 
 
 
 
 
 
 
3816 
 
 
 
 
 
 
 
3851 
 
 
 
 
 
 
 
2664 
 
 
 
 
 
 
 
4055 
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6 
6 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
 
 
 
 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
 
 
 
 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
 
 
 
 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
 
 
 
 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
 
 
 
 
569 
570 
909 
958 
823 
853 
665 
832 
830 
826 
681 
582 
779 
440 
604 
307 
4272 
321 
870 
632 
793 
576 
536 
461 
667 
541 
1052 
391 
323 
383 
418 
361 
526 
581 
506 
452 
377 
314 
338 
436 
254 
342 
 
 
 
 
569 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
631 
 
938 
989 
850 
881 
868 
859 
857 
853 
703 
601 
804 
454 
623 
317 
4409 
331 
898 
652 
819 
595 
553 
476 
689 
558 
1085 
403 
333 
395 
431 
372 
543 
600 
522 
466 
389 
324 
349 
450 
262 
353 
 
 
 
 
2527 
 
3755 
3958 
3400 
3524 
2747 
3437 
3429 
3412 
2813 
2404 
3218 
1818 
2495 
1268 
17363 
1326 
3595 
2611 
3276 
2380 
2215 
1905 
2756 
2235 
4343 
1615 
1334 
1582 
1727 
1491 
2173 
2400 
2091 
1867 
1558 
1297 
1396 
1801 
1049 
1413 
 
 
 
 
 
 
3659 
 
 
 
3256 
 
 
 
2563 
 
 
 
5681 
 
 
 
2966 
 
 
 
2278 
 
 
 
2219 
 
 
 
1948 
 
 
 
1703 
 
 
 
1415 
 
 
 
 
 
 
 86 
APPENDIX C. DMMB PELLET DATA 
 
 
Horse 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
Tx 
Group 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
IL-1 
ug/mL 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
HA 
mg/mL 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
TA 
mg/mL 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
Optical 
Density 
0.4429 
0.4832 
0.4762 
0.4722 
0.4387 
0.4127 
0.4517 
0.4745 
 
 
 
 
0.5238 
0.4895 
0.4857 
0.4713 
0.4712 
0.5002 
0.5051 
0.5144 
 
 
 
 
0.4556 
0.4960 
0.4524 
0.4764 
0.4815 
0.4604 
0.4869 
0.4609 
 
 
 
 
0.4436 
0.3892 
0.4736 
0.4810 
0.3648 
0.3586 
Chondr. 
ug/mL  
25.69 
31.89 
30.81 
30.20 
25.04 
21.04 
27.04 
30.55 
 
 
 
 
38.13 
32.86 
32.27 
30.06 
30.04 
34.50 
35.26 
36.69 
 
 
 
 
27.64 
33.86 
27.15 
30.84 
31.63 
28.38 
32.46 
28.46 
 
 
 
 
25.80 
17.43 
30.41 
31.55 
13.67 
12.72 
Total/  
Pellet 
5.13 
6.37 
6.16 
6.04 
5.01 
4.20 
5.40 
6.11 
 
 
 
 
7.62 
6.57 
6.45 
6.01 
6.00 
6.90 
7.05 
7.33 
 
 
 
 
5.52 
6.77 
5.43 
6.16 
6.32 
5.67 
6.49 
5.69 
 
 
 
 
5.16 
 
6.08 
6.31 
2.73 
2.54 
Avg for 
tx group 
5.93 
 
 
 
5.18 
 
 
 
 
 
 
 
6.66 
 
 
 
6.82 
 
 
 
 
 
 
 
5.97 
 
 
 
6.04 
 
 
 
 
 
 
 
5.85 
 
 
 
2.47 
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2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0.3456 
0.3561 
0.3539 
0.3571 
0.3466 
0.3585 
0.3615 
0.3696 
0.3584 
0.3589 
0.5099 
0.4387 
0.5088 
0.4767 
0.3335 
0.3373 
0.4032 
0.3376 
0.3626 
0.3659 
0.3642 
0.3732 
0.4024 
0.4631 
0.4152 
0.4409 
0.4125 
0.3989 
0.4205 
0.4009 
0.5218 
0.3817 
0.4785 
0.3775 
0.4647 
0.5263 
0.4885 
0.4749 
0.3818 
0.3516 
0.3950 
0.3983 
0.3424 
0.3364 
0.3681 
0.3679 
10.72 
12.33 
12.00 
12.49 
10.87 
12.70 
13.16 
14.41 
12.69 
12.76 
36.00 
25.04 
35.83 
30.89 
8.86 
9.44 
19.58 
9.49 
13.33 
13.84 
13.58 
14.96 
19.46 
28.8 
21.43 
25.38 
21.01 
18.92 
22.24 
19.23 
37.83 
16.27 
31.16 
15.63 
29.04 
38.52 
32.70 
3.61 
15.17 
10.79 
17.08 
17.56 
9.46 
8.59 
13.18 
13.15 
2.14 
2.46 
2.40 
2.49 
2.17 
2.54 
2.63 
2.88 
2.53 
2.55 
7.20 
5.00 
7.16 
6.17 
1.77 
1.88 
3.91 
1.89 
2.66 
2.76 
2.71 
2.99 
3.89 
5.76 
4.28 
5.07 
4.20 
3.78 
4.44 
3.84 
7.56 
3.25 
6.23 
3.12 
5.80 
7.70 
6.54 
6.12 
3.03 
2.15 
3.41 
3.51 
1.98 
1.71 
2.63 
2.63 
 
 
2.40 
 
 
 
2.65 
 
 
 
6.38 
 
 
 
2.36 
 
 
 
2.78 
 
 
 
4.75 
 
 
 
4.07 
 
 
 
5.04 
 
 
 
6.54 
 
 
 
3.03 
 
 
 
2.22 
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3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.4378 
 
0.3660 
0.4032 
0.4081 
0.4411 
0.4195 
0.3876 
0.3374 
0.3534 
0.3468 
0.3438 
0.3648 
0.3626 
0.3704 
0.3760 
0.4169 
0.4024 
0.4250 
0.4396 
0.3849 
0.4021 
0.4489 
0.4033 
0.4464 
0.4014 
0.4405 
 
0.4528 
0.4990 
0.4912 
0.5246 
0.3857 
0.4155 
0.3912 
0.3934 
0.3807 
0.4033 
0.4021 
0.4024 
0.4182 
0.3906 
0.4086 
0.4019 
0.4116 
0.4111 
23.28 
 
12.88 
18.27 
18.98 
23.76 
20.63 
16.01 
8.73 
11.05 
10.10 
9.66 
12.71 
12.39 
13.52 
14.33 
20.26 
18.15 
21.43 
23.55 
15.62 
18.11 
24.89 
18.28 
24.53 
18.01 
23.68 
 
25.46 
32.15 
31.02 
35.86 
55.09 
59.67 
55.94 
56.27 
54.32 
57.80 
57.61 
57.66 
60.09 
55.84 
58.61 
57.58 
59.07 
59.00 
4.65 
 
2.57 
3.65 
3.79 
4.75 
4.12 
3.20 
1.74 
2.21 
2.02 
1.93 
2.54 
2.47 
2.70 
2.86 
4.05 
3.63 
4.28 
4.71 
3.12 
3.62 
4.97 
3.65 
4.90 
3.60 
4.73 
 
5.09 
6.43 
6.20 
7.17 
11.01 
11.93 
11.18 
11.25 
10.86 
11.56 
11.52 
11.53 
12.01 
11.16 
11.72 
11.51 
11.81 
11.80 
3.62 
 
 
 
3.97 
 
 
 
1.97 
 
 
 
2.64 
 
 
 
4.17 
 
 
 
3.84 
 
 
 
4.41 
 
 
 
6.22 
 
 
 
11.34 
 
 
 
11.37 
 
 
 
11.60 
 
 
 
12.26 
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4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.4245 
0.4572 
0.4026 
0.4147 
0.3945 
0.4041 
0.3851 
0.4333 
0.3831 
0.3992 
0.3919 
0.4294 
0.4261 
0.4481 
0.4147 
0.4117 
0.3917 
 
0.4149 
0.4353 
0.4528 
0.4326 
0.4058 
0.3973 
0.4025 
0.4020 
0.4544 
0.4744 
0.4410 
0.4529 
0.4289 
0.4460 
0.4504 
0.4319 
0.4406 
 
0.4303 
0.6122 
0.4232 
0.4201 
0.4482 
0.7438 
0.4182 
0.4303 
0.4248 
0.4634 
61.06 
66.09 
57.69 
59.55 
56.44 
57.92 
55.00 
62.41 
54.69 
57.17 
56.04 
61.81 
61.30 
64.69 
59.55 
59.09 
56.01 
 
59.58 
62.72 
65.41 
62.30 
58.18 
56.87 
57.67 
57.60 
65.66 
68.74 
63.60 
65.43 
61.74 
64.37 
65.04 
62.20 
63.54 
 
61.95 
89.94 
60.86 
60.38 
64.70 
110.18 
60.09 
61.95 
61.10 
67.04 
12.21 
13.21 
11.53 
11.91 
11.28 
11.58 
11.00 
12.48 
10.93 
11.43 
11.20 
12.36 
12.26 
12.93 
11.91 
11.81 
11.20 
 
11.91 
12.54 
13.08 
12.46 
11.63 
11.37 
11.53 
11.52 
13.13 
13.74 
12.72 
13.08 
12.34 
12.87 
13.00 
12.44 
12.70 
 
12.39 
17.98 
12.17 
12.07 
12.94 
22.03 
12.01 
12.39 
12.22 
13.04 
 
 
11.58 
 
 
 
11.46 
 
 
 
12.19 
 
 
 
11.64 
 
 
 
12.50 
 
 
 
11.51 
 
 
 
13.17 
 
 
 
12.66 
 
 
 
14.36 
 
 
 
14.80 
 
 
 
12.51 
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5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.4554 
0.4301 
0.4264 
0.4359 
 
 
0.4401 
 
0.4301 
0.4470 
0.5572 
0.4453 
0.4386 
0.4493 
0.4528 
0.5682 
0.6144 
0.6477 
 
0.6045 
0.3827 
0.3960 
0.3816 
0.3824 
0.3608 
0.3765 
0.3708 
0.3741 
0.3903 
0.3536 
0.3552 
0.3546 
0.3456 
0.3545 
0.3672 
0.3784 
0.3785 
0.3814 
0.3551 
0.3815 
0.4015 
0.4002 
0.3989 
0.3850 
0.3503 
0.3947 
65.81 
61.92 
61.35 
62.81 
 
 
63.46 
 
61.92 
64.52 
81.47 
64.26 
63.23 
64.87 
65.41 
83.17 
90.27 
95.40 
 
88.75 
17.71 
19.72 
17.54 
17.66 
14.39 
16.77 
15.90 
16.40 
18.86 
13.15 
13.54 
13.45 
12.09 
13.43 
15.36 
17.06 
17.07 
17.51 
13.53 
17.53 
20.56 
20.36 
20.16 
18.06 
12.80 
19.53 
13.16 
12.38 
12.27 
12.56 
 
 
12.69 
 
12.38 
12.90 
16.29 
12.85 
12.64 
12.97 
13.08 
16.63 
18.05 
19.08 
 
17.75 
3.54 
3.94 
3.50 
3.53 
2.87 
3.35 
3.18 
3.28 
3.77 
2.63 
2.70 
2.69 
2.41 
2.68 
3.07 
3.41 
3.41 
3.50 
2.70 
3.50 
4.11 
4.07 
4.03 
3.61 
2.56 
3.90 
12.59 
 
 
 
12.69 
 
 
 
13.60 
 
 
 
13.83 
 
 
 
18.29 
 
 
 
3.63 
 
 
 
3.17 
 
 
 
2.95 
 
 
 
2.89 
 
 
 
3.28 
 
 
 
3.95 
 
 
 
3.23 
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6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.3697 
0.3759 
0.3505 
0.3724 
0.3421 
0.3725 
0.3871 
0.3874 
0.3461 
0.3852 
0.3908 
0.4075 
0.3997 
0.3856 
0.3401 
0.3704 
0.3658 
0.3982 
0.3833 
0.3816 
0.3592 
0.3669 
0.3985 
0.3960 
0.3471 
0.3681 
0.3790 
0.3602 
0.3639 
0.3562 
0.3459 
0.3516 
0.3717 
0.3192 
0.3594 
0.3794 
0.3636 
0.3465 
0.3846 
0.3998 
0.4448 
0.4444 
0.4011 
0.3751 
0.3751 
0.3359 
15.74 
16.68 
12.83 
16.15 
11.56 
16.16 
18.37 
18.42 
12.16 
18.09 
18.93 
21.46 
20.28 
18.15 
48.07 
52.74 
52.03 
57.01 
54.72 
54.46 
51.01 
52.20 
57.06 
56.67 
49.15 
52.38 
54.06 
51.17 
51.74 
50.55 
48.97 
49.84 
52.94 
44.86 
51.04 
53.43 
51.69 
49.06 
54.92 
57.26 
64.18 
64.12 
57.46 
53.46 
53.46 
47.43 
3.14 
3.33 
2.56 
3.23 
2.31 
3.23 
3.67 
3.68 
2.43 
3.61 
3.78 
4.29 
4.05 
3.63 
9.61 
10.54 
10.40 
11.40 
10.94 
10.89 
10.20 
10.44 
11.41 
11.33 
9.83 
10.47 
10.81 
10.23 
10.34 
10.11 
9.79 
9.96 
10.58 
8.97 
10.20 
10.68 
10.33 
9.81 
10.98 
11.45 
12.83 
12.82 
11.49 
10.69 
10.69 
9.48 
 
 
2.83 
 
 
 
3.35 
 
 
 
3.94 
 
 
 
10.49 
 
 
 
10.62 
 
 
 
10.76 
 
 
 
10.37 
 
 
 
9.83 
 
 
 
10.26 
 
 
 
12.02 
 
 
 
10.59 
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7 
7 
7 
7 
7 
7 
7 
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
9 
9 
9 
10 
10 
10 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
10 
10 
10 
10 
10 
10 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.3911 
0.4301 
0.4224 
0.3541 
0.4118 
0.4342 
0.3950 
0.4268 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55.92 
61.92 
60.74 
50.23 
59.10 
62.55 
56.52 
61.41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11.18 
12.38 
12.14 
10.04 
11.82 
12.51 
11.30 
12.28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11.44 
 
 
 
11.98 
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Standard curves for DMMB analysis (pellet): 
 
Horse 1 
 
DMMB Pellets
y = 0.0051x + 0.3751
R2 = 0.9357
0
0.1
0.2
0.3
0.4
0.5
0.6
0 5 10 15 20 25 30 35
ug Chondroitin/mL
O
D
5
3
0
 
Horse 2 
DMMB Pellets y = 0.0065x + 0.2759
R2 = 0.9944
0
0.1
0.2
0.3
0.4
0.5
0.6
0 5 10 15 20 25 30 35
ug Chondroitin/mL
O
D
5
3
0
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Horse 3 
 
DMMB Pellets
y = 0.0069x + 0.2771
R2 = 0.9989
0
0.1
0.2
0.3
0.4
0.5
0.6
0 5 10 15 20 25 30 35
ug Chondroitin/mL
O
D
5
3
0
 
 
Horse 4 
 
DMMB Pellets y = 0.0051x + 0.2738
R2 = 0.9863
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 10 20 30 40 50 60 70
ug Chondroitin/mL
O
D
5
3
1
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Horse 5 
 
DMMB Pellets y = 0.0051x + 0.2738
R2 = 0.9863
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 10 20 30 40 50 60 70
ug Chondroitin/mL
O
D
 5
3
0
 
 
Horse 6 
 
DMMB Pellets 
y = 0.0066x + 0.2658
R2 = 0.9865
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 10 20 30 40 50 60 70
ug Chondroitin/mL
O
D
 5
3
0
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Horse 7 
 
DMMB Pellets 
y = 0.0068x + 0.2626
R2 = 0.987
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 10 20 30 40 50 60 70
ug Chondroitin/mL
O
D
 5
3
0
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APPENDIX D. DMMB MEDIA DATA
 
Horse 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
Tx 
Group 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
IL-1 
ug/mL 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
HA 
mg/mL 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
TA 
mg/mL 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
Optical 
Density 
0.4963 
0.5174 
 
0.5202 
0.5232 
0.5629 
0.5291 
0.5313 
 
 
 
 
0.5495 
0.5369 
0.5283 
0.5420 
0.6027 
0.5566 
0.5432 
0.6010 
 
 
 
 
0.5774 
0.5952 
0.5701 
0.5995 
0.7144 
0.6896 
0.6184 
0.6711 
 
 
 
 
0.6758 
0.7058 
0.5848 
0.6964 
0.3486 
0.3707 
Chondr. 
ug/mL 
15.05 
18.75 
 
19.24 
19.77 
26.73 
20.80 
21.19 
 
 
 
 
24.38 
22.17 
20.66 
23.07 
33.71 
25.63 
23.28 
33.42 
 
 
 
 
29.28 
32.40 
28.00 
33.15 
53.31 
48.96 
36.47 
45.71 
 
 
 
 
46.54 
51.80 
30.57 
50.15 
13.42 
17.93 
Total/ 
Pellet 
7.52 
9.37 
 
9.62 
9.88 
13.36 
10.40 
10.59 
 
 
 
 
12.19 
11.08 
10.33 
11.53 
16.85 
12.81 
11.64 
16.71 
 
 
 
 
14.64 
16.20 
14.00 
16.57 
26.65 
24.48 
18.23 
22.85 
 
 
 
 
23.27 
25.90 
15.28 
25.07 
6.71 
8.96 
Avg per 
tx group 
8.84 
 
 
 
11.06 
 
 
 
 
 
 
 
11.28 
 
 
 
14.50 
 
 
 
 
 
 
 
15.35 
 
 
 
23.05 
 
 
 
 
 
 
 
22.38 
 
 
 
10.14 
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2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0.4171 
0.3926 
0.3392 
0.3587 
0.4663 
0.3975 
0.6238 
0.5782 
0.6723 
0.5816 
0.4403 
0.4906 
0.4587 
0.4217 
0.4200 
0.4797 
0.4611 
0.4602 
0.5677 
0.5606 
0.6388 
0.5600 
0.5495 
0.4665 
0.5091 
0.4359 
0.5372 
0.5686 
0.5411 
0.5482 
0.5278 
0.5709 
0.5268 
0.5197 
0.5166 
0.5554 
0.6137 
0.5845 
0.4390 
0.4652 
0.4919 
0.5150 
0.4647 
0.5415 
0.4293 
0.4534 
27.40 
22.40 
11.51 
15.48 
37.44 
23.40 
69.59 
60.28 
79.48 
60.97 
32.14 
42.40 
35.89 
28.34 
28.00 
40.18 
36.38 
36.20 
58.14 
56.69 
72.65 
56.57 
54.42 
37.48 
46.18 
31.24 
51.91 
58.32 
52.71 
54.16 
50.00 
58.79 
49.79 
48.34 
47.71 
55.63 
67.53 
61.57 
23.79 
27.70 
31.68 
35.13 
27.62 
39.08 
22.34 
25.94 
13.70 
11.20 
5.75 
7.74 
18.72 
11.70 
34.79 
30.14 
39.74 
30.48 
16.07 
21.20 
17.94 
14.17 
14.00 
20.09 
18.19 
18.10 
29.07 
28.34 
36.32 
28.28 
27.21 
18.74 
23.09 
15.62 
25.95 
29.16 
26.35 
27.08 
25.00 
29.39 
24.89 
24.17 
23.85 
27.81 
33.76 
30.78 
11.89 
13.85 
15.84 
17.56 
13.81 
19.54 
11.17 
12.97 
 
 
10.98 
 
 
 
33.79 
 
 
 
17.34 
 
 
 
17.59 
 
 
 
30.50 
 
 
 
21.16 
 
 
 
27.14 
 
 
 
25.86 
 
 
 
29.05 
 
 
 
14.78 
 
 
 
14.37 
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3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.4793 
0.4893 
0.8275 
0.4813 
0.5285 
0.7283 
0.5257 
0.5745 
0.5468 
0.5650 
0.5694 
0.5722 
0.5725 
0.5628 
0.6256 
0.5333 
0.5714 
0.6002 
0.7850 
0.6233 
0.6535 
0.6890 
0.7147 
0.6071 
0.6251 
0.6303 
0.6448 
0.6519 
0.6028 
0.6343 
0.6252 
0.6534 
0.5060 
0.4562 
0.4412 
0.5579 
0.4818 
0.4350 
0.4098 
0.5358 
0.6852 
0.6108 
0.7785 
0.7529 
0.4794 
0.5464 
29.80 
31.29 
81.77 
30.10 
37.14 
66.97 
36.73 
44.01 
39.88 
42.59 
43.25 
43.67 
43.71 
42.26 
51.64 
37.86 
43.55 
47.85 
75.43 
51.29 
55.80 
61.10 
64.94 
48.88 
51.56 
52.34 
54.50 
55.56 
48.23 
52.94 
51.58 
55.79 
41.88 
33.72 
31.26 
50.39 
37.91 
30.24 
26.11 
46.77 
71.26 
59.06 
86.55 
82.36 
37.52 
48.50 
14.90 
15.64 
40.88 
15.05 
18.57 
33.48 
18.36 
22.00 
19.94 
21.29 
21.62 
21.83 
21.85 
21.13 
25.82 
18.93 
21.77 
23.92 
37.71 
25.64 
27.90 
30.55 
32.47 
24.44 
25.78 
26.17 
27.25 
27.78 
24.11 
26.47 
25.79 
27.89 
20.94 
16.86 
15.63 
25.19 
18.95 
15.12 
13.05 
23.38 
35.63 
29.53 
43.27 
41.18 
18.76 
24.25 
21.62 
 
 
 
23.10 
 
 
 
21.17 
 
 
 
21.93 
 
 
 
27.26 
 
 
 
28.84 
 
 
 
26.74 
 
 
 
26.06 
 
 
 
19.65 
 
 
 
17.63 
 
 
 
37.40 
 
 
 
21.83 
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4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.5675 
0.4743 
0.4563 
0.5791 
0.4580 
0.5163 
0.7374 
0.7725 
0.7450 
0.6827 
0.5888 
0.6272 
0.5637 
0.5822 
0.7105 
0.6497 
0.7156 
0.6482 
0.7328 
0.6238 
0.5908 
0.7239 
0.5470 
0.6568 
0.6516 
0.5770 
0.4759 
0.4745 
0.4654 
0.4757 
0.4230 
0.4648 
0.3878 
0.3847 
0.9184 
0.8348 
0.8097 
0.8191 
0.6281 
0.5190 
0.5481 
0.6581 
0.4686 
0.5985 
0.5421 
0.4311 
51.96 
36.68 
33.73 
53.86 
34.01 
43.57 
79.81 
85.57 
81.06 
70.85 
55.45 
61.75 
51.34 
54.37 
75.40 
65.44 
76.24 
65.19 
79.06 
61.19 
55.78 
77.60 
48.60 
66.60 
65.75 
53.52 
36.95 
36.72 
35.22 
36.91 
28.27 
35.13 
22.50 
22.00 
109.49 
95.78 
91.67 
93.21 
61.90 
44.01 
48.78 
66.81 
35.75 
57.04 
47.80 
29.60 
25.98 
18.34 
16.86 
26.93 
17.00 
21.78 
39.90 
42.78 
40.53 
35.42 
27.72 
30.87 
25.67 
27.18 
37.70 
32.72 
38.12 
32.59 
39.53 
30.59 
27.89 
38.80 
24.30 
33.30 
32.87 
26.76 
18.47 
18.36 
17.61 
18.45 
14.13 
17.56 
11.25 
11.00 
54.74 
47.89 
45.83 
46.60 
30.95 
22.00 
24.39 
33.40 
17.87 
28.52 
23.90 
14.80 
 
 
20.64 
 
 
 
39.66 
 
 
 
27.86 
 
 
 
35.28 
 
 
 
34.20 
 
 
 
29.31 
 
 
 
18.22 
 
 
 
13.48 
 
 
 
48.77 
 
 
 
27.69 
 
 
 
21.27 
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5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
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6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.8370 
0.7693 
0.7144 
0.7861 
0.5909 
0.5553 
0.6535 
0.6240 
0.5490 
0.6340 
0.6535 
0.5890 
0.5962 
0.5972 
0.5849 
0.5489 
0.5849 
0.7239 
0.6313 
0.5328 
0.3979 
0.4194 
0.3967 
0.3956 
0.3576 
0.3615 
0.3710 
0.3749 
0.7418 
0.7853 
0.7591 
0.7450 
0.5272 
0.4756 
0.5152 
0.5257 
0.4451 
0.4681 
0.4646 
0.4626 
0.6400 
0.6656 
0.6442 
0.6672 
0.5901 
0.5296 
96.14 
85.04 
76.04 
87.80 
55.80 
49.96 
66.06 
61.22 
48.93 
62.86 
66.06 
55.49 
56.67 
56.83 
54.81 
48.91 
54.81 
77.60 
62.42 
46.27 
20.01 
23.27 
19.83 
19.66 
13.90 
14.50 
15.93 
16.53 
72.12 
78.71 
74.74 
72.60 
39.60 
31.78 
37.78 
39.37 
27.16 
30.65 
30.12 
29.81 
56.69 
60.57 
57.33 
60.81 
49.13 
39.96 
48.07 
42.52 
38.02 
43.90 
27.90 
24.98 
33.03 
30.61 
24.46 
31.43 
33.03 
27.74 
28.33 
28.41 
27.40 
24.45 
27.40 
38.80 
31.21 
23.13 
10.00 
11.63 
9.91 
9.83 
6.95 
7.25 
7.96 
8.26 
36.06 
39.35 
37.37 
36.30 
19.80 
15.89 
18.89 
19.68 
13.58 
15.32 
15.06 
14.90 
28.34 
30.28 
28.66 
30.40 
24.56 
19.98 
43.13 
 
 
 
29.13 
 
 
 
27.17 
 
 
 
27.15 
 
 
 
30.14 
 
 
 
10.34 
 
 
 
7.60 
 
 
 
37.27 
 
 
 
18.57 
 
 
 
14.71 
 
 
 
29.42 
 
 
 
21.14 
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2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.5273 
0.5325 
0.5788 
0.5531 
0.5621 
0.5575 
0.5591 
0.6014 
0.6057 
0.5669 
0.6244 
0.6744 
0.6198 
0.5980 
0.5054 
0.4754 
0.4167 
0.3851 
0.5110 
0.4544 
0.4268 
0.4509 
0.5498 
0.5637 
0.5779 
0.4883 
0.4514 
0.4292 
0.4375 
0.4465 
0.4571 
0.4410 
0.4710 
0.4753 
0.5854 
0.6149 
0.5858 
0.5651 
0.5530 
0.4508 
0.5449 
0.5166 
0.6579 
0.6692 
0.6226 
0.6033 
39.62 
40.40 
47.42 
43.53 
44.89 
44.19 
44.43 
50.84 
51.50 
45.62 
54.33 
61.90 
53.63 
50.33 
35.70 
31.29 
22.66 
18.01 
36.52 
28.20 
24.14 
27.69 
42.23 
44.27 
46.36 
33.19 
27.76 
24.50 
25.72 
27.04 
28.60 
26.23 
30.64 
31.27 
47.47 
51.80 
47.52 
44.48 
42.70 
27.67 
41.51 
37.35 
58.13 
59.79 
52.94 
50.10 
19.81 
20.20 
23.71 
21.76 
22.44 
22.09 
22.21 
25.42 
25.75 
22.81 
27.16 
30.95 
26.81 
25.16 
17.85 
15.64 
11.33 
9.00 
18.26 
14.10 
12.07 
13.84 
21.11 
22.13 
23.18 
16.59 
13.88 
12.25 
12.86 
13.52 
14.30 
13.11 
15.32 
15.63 
23.73 
25.90 
23.76 
22.24 
21.35 
13.83 
20.75 
18.67 
29.06 
29.89 
26.47 
25.05 
 
 
22.50 
 
 
 
24.05 
 
 
 
27.52 
 
 
 
13.45 
 
 
 
14.57 
 
 
 
20.75 
 
 
 
13.12 
 
 
 
14.59 
 
 
 
23.91 
 
 
 
18.65 
 
 
 
27.62 
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7 
7 
7 
7 
7 
7 
7 
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
9 
9 
9 
10 
10 
10 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
10 
10 
10 
10 
10 
10 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.6469 
0.6180 
0.6279 
0.6247 
0.7150 
0.8209 
0.7420 
0.6728 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56.51 
52.26 
53.72 
53.25 
66.52 
82.10 
70.50 
60.32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28.25 
26.13 
26.86 
26.62 
33.26 
41.5 
35.25 
30.16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26.96 
 
 
 
34.93 
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Standard curves for DMMB analysis (media): 
 
Horse 1 
 
DMMB Media y = 0.0057x + 0.4105
R2 = 0.9572
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 5 10 15 20 25 30 35
ug Chondroitin/mL
O
D
5
3
0
 
  
 
Horse 2 
 
DMMB Media
y = 0.0049x + 0.2828
R2 = 0.9686
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 10 20 30 40 50 60 70
ug Chondroitin/mL
O
D
5
3
0
 
 
 105 
Horse 3 
 
DMMB Media
y = 0.0067x + 0.2796
R2 = 0.9979
0
0.1
0.2
0.3
0.4
0.5
0.6
0 5 10 15 20 25 30 35
ug Chondroitin/mL
O
D
5
3
0
 
 
Horse 4 
 
DMMB Media
y = 0.0061x + 0.2505
R2 = 0.9852
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 10 20 30 40 50 60 70
ug Chondroitin/mL
O
D
5
3
1
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Horse 5 
 
DMMB Media
y = 0.0061x + 0.2505
R2 = 0.9852
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 10 20 30 40 50 60 70
ug Chondroitin/mL
O
D
 5
3
0
 
 
Horse 6 
 
DMMB Media
y = 0.0066x + 0.2658
R2 = 0.9865
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 10 20 30 40 50 60 70
ug Chondroitin/mL
O
D
 5
3
0
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Horse 7 
 
DMMB Media
y = 0.0068x + 0.2626
R2 = 0.987
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 10 20 30 40 50 60 70
ug Chondroitin/mL
O
D
 5
3
0
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APPENDIX E. DNA DATA 
 
 
Horse 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
Tx 
Group 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
IL-1 
ug/mL 
0 
0 
0 
0 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
HA 
mg/mL 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
TA 
mg/mL 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
Fluoro 
units/s 
45947 
50400 
51759 
43572 
50476 
52429 
57907 
56630 
40349 
37231 
36697 
34326 
35591 
26962 
44884 
37932 
 
 
 
 
 
 
 
 
50110 
55799 
52743 
54009 
34538 
42701 
49942 
51053 
36625 
42009 
41527 
54547 
43919 
47480 
41420 
48902 
 
 
DNA 
ug/mL 
32.85 
36.83 
38.05 
30.73 
36.90 
38.64 
43.54 
42.40 
27.85 
25.06 
24.59 
22.47 
23.60 
15.89 
31.90 
25.69 
 
 
 
 
 
 
 
 
36.57 
41.66 
38.93 
40.06 
22.66 
29.95 
36.42 
37.42 
24.52 
29.33 
28.90 
40.54 
31.04 
34.22 
28.81 
35.49 
 
 
Total/ 
Pellet 
3.28 
3.68 
3.80 
3.07 
3.69 
3.86 
4.35 
4.24 
2.78 
2.50 
2.45 
2.24 
2.36 
1.58 
3.19 
2.56 
 
 
 
 
 
 
 
 
3.65 
4.16 
3.89 
4.00 
2.26 
2.99 
3.64 
3.74 
2.45 
2.93 
2.89 
4.05 
3.10 
3.42 
2.88 
3.54 
 
 
Avg per 
tx group 
3.74 
 
 
 
 
 
 
 
2.46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.54 
 
 
 
 
 
 
 
3.16 
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1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
6 
6 
6 
6 
6 
6 
7 
7 
7 
7 
7 
7 
7 
7 
8 
8 
8 
8 
8 
8 
8 
8 
9 
9 
9 
9 
9 
9 
9 
9 
10 
10 
10 
10 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
 
 
 
 
 
 
28143 
 
 
 
39777 
 
 
 
42312 
42981 
34479 
39465 
30996 
29341 
44371 
50150 
 
 
 
 
 
 
 
 
39208 
46875 
25423 
23122 
47700 
48793 
54183 
54942 
 
26974 
38043 
25996 
27021 
26342 
24079 
21294 
 
 
 
 
 
 
16.94 
 
 
 
27.34 
 
 
 
29.60 
30.20 
22.61 
27.06 
19.49 
18.01 
31.44 
36.61 
 
 
 
 
 
 
 
 
26.83 
33.68 
14.51 
12.46 
34.42 
35.40 
40.21 
40.89 
 
13.50 
22.04 
12.74 
13.53 
13.01 
11.26 
9.11 
 
 
 
 
 
 
1.69 
 
 
 
2.73 
 
 
 
2.96 
3.02 
2.26 
2.70 
1.94 
1.80 
3.14 
3.66 
 
 
 
 
 
 
 
 
2.68 
3.36 
1.45 
1.24 
3.44 
3.54 
4.02 
4.08 
 
1.35 
2.20 
1.27 
1.35 
1.30 
1.12 
0.91 
 
 
 
 
 
 
1.89 
 
 
 
 
 
 
 
2.68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.98 
 
 
 
 
 
 
 
1.60 
 
 
 
1.17 
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2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
36552 
46523 
53013 
35275 
32503 
29088 
22061 
31271 
29047 
29461 
30644 
31494 
32289 
38016 
28609 
35389 
44990 
33956 
49305 
41644 
 
34526 
33053 
36380 
34706 
41793 
26215 
47604 
29916 
49609 
65000 
26065 
21792 
21179 
23365 
23953 
23514 
24806 
25654 
24405 
23050 
 
21298 
23419 
 
25134 
20.89 
28.58 
33.59 
19.90 
17.76 
15.13 
 
16.81 
15.10 
15.42 
16.33 
16.99 
17.60 
22.02 
14.76 
19.99 
27.40 
18.89 
30.73 
24.82 
 
19.33 
18.19 
20.76 
19.46 
24.93 
12.91 
29.42 
15.77 
30.97 
42.84 
12.80 
9.10 
8.71 
10.11 
10.49 
10.21 
11.04 
11.59 
10.78 
9.91 
 
8.78 
10.15 
 
11.25 
2.08 
2.85 
3.35 
1.99 
1.77 
1.51 
 
1.68 
1.51 
1.54 
1.63 
1.69 
1.76 
2.20 
1.47 
1.99 
2.74 
1.88 
3.07 
2.48 
 
1.93 
1.81 
2.07 
1.94 
2.49 
1.29 
2.94 
1.57 
3.09 
4.28 
1.28 
0.91 
0.87 
1.01 
1.04 
1.02 
1.10 
1.15 
1.07 
0.99 
 
0.87 
1.01 
 
1.12 
2.57 
 
 
 
1.65 
 
 
 
1.59 
 
 
 
1.85 
 
 
 
2.54 
 
 
 
1.94 
 
 
 
2.16 
 
 
 
2.55 
 
 
 
0.96 
 
 
 
1.09 
 
 
 
0.96 
 
 
 
1.14 
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3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
0 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0.5 
0.5 
2.0 
2.0 
2.0 
2.0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.06 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0.6 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0.06 
0.06 
0.06 
0.06 
24491 
26765 
18926 
24689 
20745 
24784 
25432 
24932 
26784 
24276 
26167 
25370 
27258 
33353 
23735 
24372 
22563 
26012 
33997 
22373 
22506 
25793 
 
37595 
21359 
33717 
25068 
36713 
36050 
40910 
26989 
24942 
35423 
38461 
39093 
34355 
36428 
40257 
39525 
39221 
34936 
36545 
35459 
36826 
43863 
31431 
10.84 
12.30 
7.26 
10.97 
8.43 
11.03 
11.44 
11.12 
12.32 
10.70 
11.92 
11.40 
12.62 
16.54 
10.35 
10.76 
9.60 
11.82 
16.96 
9.48 
9.56 
11.68 
 
19.27 
8.82 
16.78 
11.69 
21.55 
20.99 
25.10 
13.31 
11.58 
20.46 
23.03 
23.56 
19.55 
21.31 
24.55 
23.93 
23.67 
20.04 
21.41 
20.49 
21.64 
27.60 
17.08 
1.08 
1.23 
0.72 
1.09 
0.84 
1.10 
1.14 
1.11 
1.23 
1.07 
1.19 
1.14 
1.26 
1.65 
1.03 
1.07 
0.96 
1.18 
1.69 
0.94 
0.95 
1.16 
 
1.92 
0.88 
1.67 
1.16 
2.15 
1.09 
1.51 
1.33 
1.15 
2.04 
2.30 
2.35 
1.95 
2.13 
2.45 
2.39 
2.36 
2.00 
2.14 
2.04 
2.16 
2.76 
1.70 
 
 
0.94 
 
 
 
1.14 
 
 
 
1.31 
 
 
 
1.06 
 
 
 
1.19 
 
 
 
1.49 
 
 
 
1.98 
 
 
 
1.70 
 
 
 
2.22 
 
 
 
2.22 
 
 
 
2.17 
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4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
7 
7 
8 
8 
8 
8 
9 
9 
9 
9 
10 
10 
10 
10 
1 
1 
1 
1 
2 
2 
2 
2 
3 
3 
3 
3 
4 
4 
4 
4 
5 
5 
5 
5 
6 
6 
6 
6 
7 
7 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
0 
0 
0 
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Standard curves for DNA analysis: 
 
Horse 1 
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Horse 2 
 
DNA Pellets
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Horse 3 
 
DNA Pellets
y = 1553.4x + 7646
R2 = 0.9973
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Horse 4 
 
DNA Pellets y = 1180.7x + 11264
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Horse 5 
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Horse 6 
 
DNA Pellets y = 1611.5x + 7706.8
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Horse 7 
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